TITLE 856 INDIANA BOARD OF PHARMACY

ARTICLE 1. PHARMACIES AND PHARMACISTS

Rule 1. Application Requirements *(Repealed)*
(Repealed by Indiana Board of Pharmacy; filed Dec 3, 1985, 3:02 pm: 9 IR 771)

Rule 1.1. Definitions

856 IAC 1-1.1-1 Adoption of definitions
  Authority: IC 25-26-13-4
  Affected: IC 25-26-13-2

Sec. 1. All terms which are defined in IC 25-26-13-2 shall have the same meanings as they are so defined when used in the rules and regulations of the Indiana board of pharmacy found in Article 1 of Title 856 of the Indiana Administrative Code. *(Indiana Board of Pharmacy; 856 IAC 1-1.1-1; filed Dec 3, 1985, 3:02 pm: 9 IR 767; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; errata filed Jan 9, 2002, 4:20 p.m.: 25 IR 1645; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)*

856 IAC 1-1.1-2 "Pharmacy Practice Act" defined
  Authority: IC 25-26-13-4
  Affected: IC 25-26-13


856 IAC 1-1.1-3 "In personal attendance" defined
  Authority: IC 25-26-13-4
  Affected: IC 25-26-13; IC 25-26-13-2

Sec. 3. "In personal attendance", for the purposes of IC 25-26-13-18(a) of the Pharmacy Practice Act, means being physically present in the area specified as the dimensions of the pharmacy in the relevant pharmacy permit application. This section in no way restricts functions listed under the practice of pharmacy definition in IC 25-26-13-2 that are unrelated to the direct filling, dispensing, distribution, and storage of a legend drug product. *(Indiana Board of Pharmacy; 856 IAC 1-1.1-3; filed Dec 3, 1985, 3:02 p.m.: 9 IR 767; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; errata filed Jan 9, 2002, 4:20 p.m.: 25 IR 1645; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)*

856 IAC 1-1.1-4 "Reasonable visual and vocal distance" defined
  Authority: IC 25-26-13-4
  Affected: IC 25-26-13-18

Sec. 4. The standard for "reasonable visual and vocal distance", as found in IC 25-26-13-18(a)(4) of the Pharmacy Practice Act, can be met by a pharmacist being physically present within the licensed permitted area or by a means that provides for adequate supervision of technicians as individually approved by the board. *(Indiana Board of Pharmacy; 856 IAC 1-1.1-4; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)*
856 IAC 1-1.1-5 "Supervision" defined
Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 5. For purposes of this article, "supervision" means the physical or real-time act of oversight and management by a managing pharmacist, pharmacist in charge, or qualifying pharmacist of another individual's work or work product. Unless otherwise stated in this article, individuals practicing pharmacy must be directly supervised either through a direct line of sight and hearing, or via technological means that allow a supervisor to adequately ensure quality of care and patient services. In accordance with other sections in this article, if a facility is using technology to allow indirect supervision, they must have documented policies and procedures and other adequate safeguards to protect against patient harm, diversion, and privacy incidents. (Indiana Board of Pharmacy; 856 IAC 1-1.1-5; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-1.1-6 "Pharmaceutical care" defined
Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 6. For purposes of this article, "pharmaceutical care" includes the spectrum of services and products provided by a board licensee to a patient or consumer in the normal course of practice. The term includes, but is not limited to, dispensing legend drug product and delivery of cognitive services. (Indiana Board of Pharmacy; 856 IAC 1-1.1-6; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-1.1-7 "Real-time online database" defined
Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 7. "Real-time online database" means a database that is continuously updated in real time and allows users to share and store patient information and interface with each other in a secure environment over the Internet or an intranet. Where appropriate, facilities or companies utilizing this type of database will comply with other applicable federal or state laws and regulations that govern e-commerce, privacy, access, or sharing of patient information, such as, but not limited to, U.S. Drug Enforcement Administration regulations that outline what information must be maintained and included in any electronic transfer transaction. (Indiana Board of Pharmacy; 856 IAC 1-1.1-7; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-1.1-8 "Unlicensed person" defined
Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 8. "Unlicensed person" means any individual that is not HIPAA trained and does not hold a valid license, certification, permit, or registration issued by the board. Unlicensed persons are prohibited from performing pharmacy dispensing functions related to legend drug product in the pharmacy dispensing environment. The pharmacy dispensing environment includes the secured area where legend drug product is stored, reviewed, bottled, and dispensed (this does not include palleted legend drug product not yet reviewed or received by the pharmacist staff and held in a separate or distinct storage area). This prohibition does not apply to the presence of supervised cleaning staff, delivery personnel, or individuals present on site to perform administrative or operational functions and directly supervised by the pharmacist. (Indiana Board of Pharmacy; 856 IAC 1-1.1-8; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)
856 IAC 1-1.1-9 "Electronic database" defined
Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 9. "Electronic database" means a record of information stored electronically that can be accessed using applications designed to securely store, retrieve, and organize information required to be maintained according to applicable state and federal pharmacy laws and regulations. (Indiana Board of Pharmacy; 856 IAC 1-1.1-9; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-1.1-10 "Electronic record or image" defined
Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 10. "Electronic record or image" means a record or image capable of being copied, reproduced, or created via technology designed to capture information in one form and reproduce it in an electronic medium presentable and usable to an end user. For example, an electronic image could be a scanned version of a written prescription. An electronic record or image must be capable of being securely stored and retrieved after the date of creation for subsequent use or evaluation, or both. Such a record or image once created shall be unalterable but may be annotated as necessary so long as the original record or image is still available for review and the individual that made the annotation is noted. (Indiana Board of Pharmacy; 856 IAC 1-1.1-10; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

Rule 2. Pharmacists' Certificate

856 IAC 1-2-1 Display of certificate
Authority: IC 25-26-13-4
Affected: IC 25-26-13-4; IC 25-26-13-11

Sec. 1. Certificates of licensure shall be conspicuously displayed in the drugstore, pharmacy, hospital, dispensary or other place where drugs are sold or dispensed and where the owner or holder thereof is in employment. Failure to comply with this rule shall be deemed sufficient cause for suspension or revocation of the license. (Indiana Board of Pharmacy; Reg 2, Sec 1; filed Jun 18, 1962, 10:00 a.m.: Rules and Regs. 1963, p. 119; readopted filed Dec 2, 2001, 12:35 p.m.: 25 IR 1331; readopted filed Sep 26, 2008, 10:55 a.m.: 20081015-IR-856080346RFA; readopted filed Dec 1, 2014, 8:33 a.m.: 20141231-IR-856140392RFA; readopted filed Oct 6, 2020, 12:03 p.m.: 20201104-IR-856200443RFA)

856 IAC 1-2-2 Illegal display of certificate; prohibition
Authority: IC 25-26-13-4
Affected: IC 25-26-13-4; IC 25-26-13-11

Sec. 2. The display of a certificate of licensure as a pharmacist in a drugstore, pharmacy, hospital, dispensary, or other place where drugs are sold or dispensed, and in which place the owner and holder of such license is not in bona fide employment, shall be deemed an illegal use of such license, and upon satisfactory proof of such illegal use, such license may be revoked. (Indiana Board of Pharmacy; Reg 2, Sec 2; filed Jun 18, 1962, 10:00 a.m.: Rules and Regs. 1963, p. 119; readopted filed Dec 2, 2001, 12:35 p.m.: 25 IR 1331; readopted filed Sep 26, 2008, 10:55 a.m.: 20081015-IR-856080346RFA; readopted filed Dec 1, 2014, 8:33 a.m.: 20141231-IR-856140392RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-2-3 Notification of address change
Authority: IC 25-26-13-4
Affected: IC 25-26-13-4; IC 25-26-13-11
Sec. 3. All holders of a license as a pharmacist shall notify the Indiana board of pharmacy of any change of address. *(Indiana Board of Pharmacy; Reg 2, Sec 3; filed Jun 18, 1962, 10:00 a.m.: Rules and Regs. 1963, p. 119; readopted filed Dec 2, 2001, 12:35 p.m.: 25 IR 1331; readopted filed Sep 26, 2008, 10:55 a.m.: 20081015-IR-856080346RFA; readopted filed Dec 1, 2014, 8:33 a.m.: 20141231-IR-856140392RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)*

856 IAC 1-2-4 Service by mail sufficient notice

Authority: IC 25-26-13-4
Affected: IC 25-26-13-4; IC 25-26-13-11

Sec. 4. The Board has no way of knowing whether or not a notice reaches its destination and, therefore, when a notice has been mailed to the person concerned, the duty of the Board has been performed. *(Indiana Board of Pharmacy; Reg 2, Sec 4; filed Jun 18, 1962, 10:00 am: Rules and Regs. 1963, p. 119; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)*

856 IAC 1-2-5 Duplicate certificate or drugstore permit; fees *(Repealed)*

Sec. 5. *(Repealed by Indiana Board of Pharmacy; filed Aug 12, 1987, 9:45 am: 11 IR 94)*

**Rule 3. Experience *(Repealed)***

*(Repealed by Indiana Board of Pharmacy; filed Dec 3, 1985, 3:02 pm: 9 IR 771)*

**Rule 3.1. Examination and Experience Requirements**

856 IAC 1-3.1-1 Licensure by examination

Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 1. All pharmacist applicants for licensure by examination qualified by law and as provided in rules of the board shall take the complete examination consisting of North American Pharmacist Licensure Examination (NAPLEX™) and the Multistate Pharmacy Jurisprudence Examination (MPJE™). All exams shall be given in the English language only. *(Indiana Board of Pharmacy; 856 IAC 1-3.1-1; filed Dec 3, 1985, 3:02 p.m.: 9 IR 767; filed Apr 23, 1999, 2:06 p.m.: 22 IR 2876; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)*

856 IAC 1-3.1-2 Information for licensure

Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 2. (a) Persons seeking licensure by examination shall file an application on a form supplied by the board.
(b) Persons seeking licensure by examination shall provide the following information on, or submit such information with, the application for licensure:
(1) Complete name, address, and telephone number.
(2) Date and place of birth.
(3) Certification of complete history and structure of hours of pharmacy experience prior to and after graduation.
(4) Intern/extern certificate number, including date and state from which certificate was issued.
(5) Two (2) recent passport-type (2”× 2”) photographs of the applicant, taken within eight (8) weeks prior to filing the application.
(6) The fee as required by 856 IAC 1-27-1.
(7) Either:
(A) certification of graduation from a program approved by the board pursuant to 856 IAC 1-5-1; or
(B) in the case of an applicant applying in the last half-year of the curriculum, certification from the dean of an approved pharmacy program that the applicant is expected to successfully complete the curriculum;

however, the applicant shall not be allowed to sit for the examination until the board has received certification of graduation.

Sec. 3. To successfully pass an examination, the applicant must attain a general average of not less than seventy-five (75) on the examination taken after the effective date of this rule.

Sec. 4. If an applicant fails an examination or any portion of an examination and wishes to retake the failed portions, the applicant shall file a new complete application, except that the applicant may include affidavits or data concerning his or her experience in a pharmacy and attendance at a college or school of pharmacy by referring to the original application. An applicant who fails to pass a portion of the examination after two (2) sittings shall be permitted to take subsequent examinations, providing the candidate first both appears before the board for consultation, and receives the express written permission of the board.

Sec. 5. The period of practical experience required by law for an applicant for a pharmacist license shall be computed and credited from the date of registration as a pharmacist intern/extern, with no credit given for any experience in pharmacy prior to registration or during a period when the registration has lapsed or is suspended or revoked by the board.

Sec. 6. (a) The Indiana board of pharmacy (board) shall approve all practical experience programs wherever served. Persons
responsible for the integrity and content of practical experience programs shall furnish information regarding material changes to
the board, prior to implementation, for approval of the program. Approval may be withheld for cause, which may include, but is not
limited to, unapproved material change in the program or change in program administration.

(b) All persons wishing to satisfy their practical experience requirements in Indiana shall possess a valid registration as a
pharmacist intern or extern in Indiana while the practical experience hours are being served.

(c) If the experience is in a pharmacy that is required by law to have a pharmacy permit, that pharmacy must have a valid
pharmacy permit. A pharmacy permit is not required if:

(1) the practical experience is being obtained at a site other than a pharmacy, for example, sites primarily engaged in:
   (A) manufacturing;
   (B) research;
   (C) consulting;
   (D) drug information;
   (E) drug utilization review; or
   (F) other pharmacy-related activity; or

(2) the experience is in a pharmacy that is not required to have a permit, for example, federally owned facilities.

(d) Prior approval is required for experience in a site other than a pharmacy. A written request must be submitted to the board
prior to beginning the experience period if:

(1) an individual intern or preceptor is seeking board approval, the request for approval shall include:
   (A) a detailed description of the proposed practical experience program with respect to time, place, duties,
       responsibilities, and supervision; and
   (B) the name of the person responsible for supervising the experience; or

(2) an approved college or school of pharmacy is seeking board approval for experiential courses, the request for approval shall
include:
   (A) a detailed description of the proposed practical experience course with respect to duties, responsibilities, and
       supervision; and
   (B) the name of the course coordinator responsible for site selection and maintenance of the integrity of the program.

(e) Acceptable practical experience time per week shall consist of not less than four (4) and not more than sixty (60) hours of
time per week served under the supervision of a pharmacist or another board approved practical experience supervisor. (Indiana
Board of Pharmacy; 856 IAC 1-3.1-6; filed Dec 3, 1985, 3:02 p.m.; 9 IR 768; filed Apr 23, 1999, 2:06 p.m.; 22 IR 2876; readopted
filed Dec 2, 2001, 12:35 p.m.; 25 IR 1331; readopted filed Oct 4, 2007, 3:33 p.m.; 20071031-IR-856070060RFA; readopted filed
Nov 25, 2013, 9:24 a.m.; 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.; 20191218-IR-856190076RFA)

856 IAC 1-3.1-7 Pharmacist intern/extern; program requirements

Sec. 7. (a) Practical experience requirements for pharmacist interns/externs in Indiana may be satisfied by complying with
either of the following:

(1) Completion of the practical experience requirements of the college or school of pharmacy from which the intern/extern
has graduated, if the curriculum of the college or school has been accredited by:
   (A) the American Council on Pharmaceutical Education (ACPE);
   (B) the Canadian Council on Pharmacy Accreditation (CCPA); or
   (C) another board-approved practical experience program.

(2) In the event the intern/extern has graduated from a nonaccredited program as outlined in subdivision (1) or has no practical
experience as a part of that individual's educational curriculum, the intern/extern must complete a minimum of one thousand
five hundred (1,500) hours of practical experience under the supervision of a pharmacist and provide the board, prior to or
concurrent with application for licensure, a written description of the objectives and duties of that experience.

(b) If a candidate for licensure as a pharmacist in Indiana has been licensed as a pharmacist in another state or jurisdiction and
has been engaged in the practice of pharmacy as defined in IC 25-26-13-2 for a period of not less than one (1) year, the practical
experience requirement is waived. (Indiana Board of Pharmacy; 856 IAC 1-3.1-7; filed Dec 3, 1985, 3:02 p.m.; 9 IR 768; filed Jan
856 IAC 1-3.1-8 Pharmacist intern/extern; minimum/maximum hours of supervision (Repealed)

Sec. 8. (Repealed by Indiana Board of Pharmacy; filed Apr 23, 1999, 2:06 p.m.: 22 IR 2878)

856 IAC 1-3.1-9 Pharmacist intern/extern; practical experience affidavits

Authority: IC 25-26-13-4
AFFECTED: IC 25-26-13

Sec. 9. The acceptable pharmacist intern or pharmacist extern practical experience time must be verified by practical experience affidavits signed at the termination of each period of practical experience. All such affidavits must list all practical experience time on a calendar week basis showing actual time served each week. (Indiana Board of Pharmacy; 856 IAC 1-3.1-9; filed Dec 3, 1985, 3:02 p.m.: 9 IR 768; filed Apr 23, 1999, 2:06 p.m.: 22 IR 2877; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-3.1-10 Pharmacist intern/extern; unacceptable experience time (Repealed)

Sec. 10. (Repealed by Indiana Board of Pharmacy; filed Dec 2, 2001, 12:35 p.m.: 25 IR 1340)

856 IAC 1-3.1-11 Out-of-state externship and other practical experience programs; postgraduate requirements; taking the licensure examination before completion of practical experience

Authority: IC 25-26-13-4
AFFECTED: IC 25-26-13-11

Sec. 11. (a) Time accepted for experience gained in approved school supervised practical experience programs in other states successfully completed while enrolled in a professional degree program recognized under IC 25-26-13-11(a)(3) will be credited toward fulfillment of experience hours required under section 7 of this rule. Time accepted for practical experience obtained while not enrolled in a professional degree program and approved under section 6 of this rule may be credited to experience requirements at the board's discretion, whether or not served in Indiana.

(b) A description of the out-of-state practical experience program with the number of hours it contains shall be submitted with the certification for evaluation by the board subject to the following:

(1) Students supplying detailed information on their program at least eight (8) weeks in advance of the board examination date will have their hours evaluated to determine the number that will be accepted toward the prelicensure five hundred twenty (520) hour requirement.

(2) Students not supplying sufficient detailed information on their program or failing to submit the same within eight (8) weeks before the board examination to allow evaluation may take the exam prior to the evaluation of their program. After evaluation, they will be notified of the hours that may be accepted. If sufficient hours are not accepted, licensure will not be granted.

(c) A candidate for licensure who has graduated from an approved school of pharmacy may take the examination before completing the required practical experience hours. However, the candidate will not be licensed as a pharmacist until affidavits are received for the entire practical experience requirement. (Indiana Board of Pharmacy; 856 IAC 1-3.1-11; filed Dec 3, 1985, 3:02 p.m.: 9 IR 768; errata, 9 IR 1101; filed Apr 23, 1999, 2:06 p.m.: 22 IR 2877; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)
Sec. 12. Practical experience time served in another state will be accepted and will permit the applicant to take the NAPLEX examination subject to section 11 of this rule if the following requirements are met:

1. The practical experience time served in such other state meets all requirements of Indiana law and is experience time of the type that is acceptable to the Indiana board of pharmacy (board).

2. The applicant has a valid intern or apprentice license from the state where the experience is served. Or, if that other state does not require an intern or apprentice license, the applicant must submit certification or an affidavit from the secretary of the board that no intern or apprentice license is required.

Sec. 13. Any misrepresentation made or any fraud perpetrated in an application for examination, or in the examination, shall be deemed sufficient cause for the refusal of such application, or to complete such examination, and if such misrepresentation or fraud is not discovered until later than at the time of the submission of such application, or until the completion of such examination, it shall be deemed sufficient cause for the dismissal from the examination, or the refusal to grant a certificate, or the revocation of the certificate if already issued, and the fee paid with such application for such examination shall be forfeited; provided, however, that the action of the board shall be subject to the law in force with respect to the denial of a license or permit on application.

Sec. 1. All applicants for license transfer registration must submit their application, with a certified photograph of the applicant and if necessary a copy of their birth certificate attached thereto, and may be requested to appear in person before the Indiana board of pharmacy (board) for a personal interview during a board meeting. An Indiana law examination must be passed before any certificate of licensure will be issued. A practical examination will be administered to the applicant if the board determines that the applicant has not been actively practicing pharmacy in the twelve (12) months preceding the application. An Indiana law examination must be passed before any certificate of licensure will be issued. A practical examination will be administered to the applicant if the board determines that the applicant has not been actively practicing pharmacy in the twelve (12) months preceding the application. Applications for license transfer must be reviewed and approved at a board meeting prior to examination and prior to the applicant's board requested personal appearance.

Sec. 2. Application forms

Authority: IC 25-26-13-4
Affected: IC 25-26-13-4; IC 25-26-13-11
Sec. 2. All applicants applying for license transfer in Indiana are required to make application on the official application blanks issued by the National Association of Boards of Pharmacy. (Indiana Board of Pharmacy: Reg 4,Sec 2; filed Jun 18, 1962, 10:00 a.m.: Rules and Regs. 1963, p. 119; readopted filed Dec 2, 2001, 12:35 p.m.: 25 IR 1333; readopted filed Sep 26, 2008, 10:55 a.m.: 20081015-IR-856080346RFA; readopted filed Dec 1, 2014, 8:33 a.m.: 20141231-IR-856140392RFA; readopted filed Oct 6, 2020, 12:03 p.m.: 20201104-IR-856200443RFA)

856 IAC 1-4-3 Restoration of Indiana certification by reciprocity (Repealed)

Sec. 3. (Repealed by Indiana Board of Pharmacy; filed Apr 23, 1999, 2:06 p.m.: 22 IR 2878)

856 IAC 1-4-4 Qualifications of applicants for license transfer

Authority: IC 25-26-13-4
Affected: IC 25-26-13-4; IC 25-26-13-11

Sec. 4. Applicants for license transfer will be admitted to Indiana only if their qualifications for licensure, possessed at the time of their original registration in the state from which they came, were equal to the requirements of Indiana at that time. (Indiana Board of Pharmacy: Reg 4,Sec 4; filed Jun 18, 1962, 10:00 a.m.: Rules and Regs. 1963, p. 120; readopted filed Dec 2, 2001, 12:35 p.m.: 25 IR 1333; readopted filed Sep 26, 2008, 10:55 a.m.: 20081015-IR-856080346RFA; readopted filed Dec 1, 2014, 8:33 a.m.: 20141231-IR-856140392RFA; readopted filed Oct 6, 2020, 12:03 p.m.: 20201104-IR-856200443RFA)

Rule 5. Recognition of Accredited Schools

856 IAC 1-5-1 Recognition of accredited schools or colleges (Repealed)

Sec. 1. (Repealed by Indiana Board of Pharmacy; filed Dec 2, 2001, 12:35 p.m.: 25 IR 1340)

Rule 6. Drugstores, Pharmacies, Apothecary Shops (Repealed)
(Repealed by Indiana Board of Pharmacy; filed Jun 20, 2001, 3:59 p.m.: 24 IR 3651)

Rule 6.1. Drugstores, Pharmacies, Apothecary Shops

856 IAC 1-6.1-1 Pharmacy equipment; lack of access between adjacent pharmacies

Authority: IC 25-26-13-4
Affected: IC 25-26-13-18

Sec. 1. (a) In addition to the requirements of IC 25-26-13-18, the qualifying pharmacist for each pharmacy issued a permit by the board shall be responsible for all decisions concerning the additional fixtures, facilities, and equipment needed by the pharmacy to operate properly in compliance with the law regulating pharmacies. In making those decisions, the qualifying pharmacist shall consider minimum health, safety, and security measures as well as the type and scope of practice, the patient's needs, and the laws and rules that apply.

(b) If requested by a representative of the Indiana board of pharmacy (board), the qualifying pharmacist shall justify, in writing, all decisions made under this rule.

(c) The board shall determine whether minimum health, safety, and security measures have been satisfactorily met by an applicant for a pharmacy permit before the permit is issued or at any time the permit is in effect.

(d) If the board determines that a pharmacy does not meet the requirements of IC 25-26-13-18 and this rule, it will identify and notify the qualifying pharmacist of the deficiencies. The qualifying pharmacist shall correct or cause to be corrected the deficiencies identified within thirty (30) days of notification by the board of the noncompliance.

(e) Failure to timely correct the deficiencies identified is grounds for denial or revocation of a permit.

(f) To assure that no pharmacy is left unattended by a pharmacist while that pharmacy is in operation, no means of access may be constructed or maintained between adjacent pharmacies. (Indiana Board of Pharmacy: 856 IAC 1-6.1-1; filed Jun 20, 2001, 3:59 p.m.)
Rule 7. Pharmacy Permits

856 IAC 1-7-1 Change of pharmacy ownership (Expired)
Sec. 1. (Expired under IC 4-22-2.5, effective January 1, 2020.)

856 IAC 1-7-2 Application for permit to conduct pharmacy (Expired)
Sec. 2. (Expired under IC 4-22-2.5, effective January 1, 2020.)

856 IAC 1-7-3 Relocation of pharmacy (Expired)
Sec. 3. (Expired under IC 4-22-2.5, effective January 1, 2020.)

856 IAC 1-7-4 Licensed pharmacist required for each pharmacy (Expired)
Sec. 4. (Expired under IC 4-22-2.5, effective January 1, 2020.)

856 IAC 1-7-5 Pharmaceutical consultation service for extended care facilities; notice to board (Expired)
Sec. 5. (Expired under IC 4-22-2.5, effective January 1, 2003.)

856 IAC 1-7-6 Consulting pharmacist and dispensing pharmacist; definitions (Expired)
Sec. 6. (Expired under IC 4-22-2.5, effective January 1, 2003.)

856 IAC 1-7-7 Duties of consulting pharmacist (Expired)
Sec. 7. (Expired under IC 4-22-2.5, effective January 1, 2003.)

Rule 8. Known Pharmaceutical Manufacturer and Manufacturer–Definition

856 IAC 1-8-1 Known pharmaceutical manufacturer; definition (Repealed)
Sec. 1. (Repealed by Indiana Board of Pharmacy; filed Dec 3, 1985, 3:02 pm: 9 IR 771)

856 IAC 1-8-2 "Manufacturer" defined (Repealed)
Sec. 2. (Repealed by Indiana Board of Pharmacy; filed Feb 11, 1981, 9:05 am: 4 IR 379)

Rule 9. Application for Prohibited Drugs (Repealed)
(Repealed by Indiana Board of Pharmacy; filed Feb 11, 1981, 9:05 am: 4 IR 379)

Rule 10. Non-Drug Products (Repealed)
(Repealed by Indiana Board of Pharmacy; filed Dec 3, 1985, 3:02 pm: 9 IR 771)
Rule 11. Toxic Preparations (Repealed)
(Repealed by Indiana Board of Pharmacy; filed Dec 3, 1985, 3:02 pm: 9 IR 771)

Rule 12. Poisons (Repealed)
(Repealed by Indiana Board of Pharmacy; filed Dec 2, 2001, 12:35 p.m.: 25 IR 1340)

Rule 13. General Definitions

856 IAC 1-13-1 Calendar week (Repealed)
Sec. 1. (Repealed by Indiana Board of Pharmacy; filed Dec 3, 1985, 3:02 pm: 9 IR 771)

856 IAC 1-13-2 "Be in personal attendance" defined (Repealed)
Sec. 2. (Repealed by Indiana Board of Pharmacy; filed Dec 3, 1985, 3:02 pm: 9 IR 771)

856 IAC 1-13-3 "Prescription department closed" closing hours; electronic monitoring; applicability
Authority: IC 25-26-13-4
Affected: IC 25-26-13-10; IC 25-26-13-19

Sec. 3. (a) This section and section 4 of this rule implement IC 25-26-13-19 concerning board approval for Type I and Type VI pharmacies to be opened to the general public without a pharmacist on duty. This section and section 4 of this rule apply only in situations where the entire area of the business is licensed as a pharmacy. This section, section 4 of this rule, and IC 25-26-13-19 do not apply where the only area of a business licensed as a pharmacy is the prescription department.

(b) The following definitions apply throughout this section:
(1) "Absence of pharmacist" means those periods when the prescription department is closed and secured and the pharmacist is not present in the pharmacy.
(2) "Electronic monitoring system" means a system having the ability by light beam, heat, motion, or other electronically activated method to detect the presence of unauthorized persons or instrumentalities in a given area, and relay or report that detection as described in this section.
(3) "Prescription department" means that area of the pharmacy where the legend drugs, devices, and other merchandise or items which can only be dispensed or delivered by a pharmacist are located and which must be secured in the absence of the pharmacist.
(4) "Reasonable barrier" means an obstruction or barricade that blocks or impedes the entry into the area by an ordinary person, and includes, but is not limited to, a latched or locked gate of sufficient height and construction that an ordinary person cannot breach the barrier and/or violate the space being monitored without detection.
(5) "Secured" means either of the following:
   (A) An area is completely enclosed as to its perimeter, from floor to ceiling, and locked.
   (B) Through installation of reasonable barriers, an area not readily accessible which is monitored by a board approved electronic monitoring system covering all portions of the secured areas.

(c) Before a pharmacy may be open to the general public without a pharmacist on duty, the pharmacy must file an application with the board and have it approved by the board under IC 25-26-13-19. The pharmacy must abide by the closing hours designated in the application. Any change from the hours as stated in the application must be submitted in writing to the board.

(d) Under IC 25-26-13-19, a prescription department may be locked or secured while the remainder of the pharmacy remains open to the public if the following criteria are met:
   (1) The prescription department is constructed in such a manner or located in such an area that reasonable barriers are in place which prevent the easy and/or quick access to legend drugs and other articles which are in the prescription department. These barriers may be doors or other obstacles as the occasion requires.
   (2) The prescription department, if not secured and locked as described in subsection (b)(5)(A), must be secured and monitored by a board approved electronic monitoring device that provides the following:
(A) On-site audible alarm that is clearly and continuously audible at all points within the pharmacy.
(B) Off-site audible or visual alarm that is continuously monitored at all times that the pharmacy remains open while the prescription department is closed and secured.

(3) Any violation or breach of the secured area shall be duly recorded by the qualifying pharmacist of the pharmacy and by the off-site security monitoring agency and reported to the board within seventy-two (72) hours of the violation or breach. The report shall include the nature of the violation or breach.

(4) Facilities monitored electronically must provide for backup power for the eventuality that there is an electronic power failure for any reason. Such backup power shall be capable of continuing the monitoring for a period of no less than thirty-six (36) hours.

(5) The electronic monitoring system shall be activated and inactivated only by key or combination. Alarms which have been triggered shall only be reset and/or reactivated by a pharmacist. The key or combination shall only be in the possession or knowledge of a pharmacist. Reasonable exceptions shall be made to this for security system operators. However, in no case shall a security system operator have access to the secured area without the presence of a pharmacist. Such exceptions shall be listed in the application under this section and shall be subject to approval by the board.

(c) Under IC 25-26-13-10(b), the board may revoke or limit the privilege to be open to the general public without a pharmacist on duty if the pharmacy violates this section or section 4 of this rule.

856 IAC 1-13-4 Record of hours open without a pharmacist on duty

Authority: IC 25-26-13-4; IC 25-26-13-19
Affected: IC 25-26-13-4; IC 25-26-13-19

Sec. 4. The pharmacist shall maintain a record stating any hours that the pharmacy has been open for business without having a pharmacist on duty if those hours vary from the hours listed in the application under section 3(c) of this rule. Entries in this written record shall be made in ink of the time the pharmacist is absent. The written record shall be maintained in the pharmacy and shall be available for examination by members of the board or their inspectors for a period of not less than two (2) years from the date of the last entry in the record.

856 IAC 1-13-5 Legend drugs (Repealed)

Sec. 5. (Repealed by Indiana Board of Pharmacy; filed Dec 3, 1985, 3:02 pm: 9 IR 771)

Rule 14. Physical Inventory of Merchandise (Repealed)
(Repealed by Indiana Board of Pharmacy; filed Dec 3, 1985, 3:02 pm: 9 IR 771)

Rule 15. Pharmacists' Notification of Termination

856 IAC 1-15-1 Pharmacist leaving employ of pharmacy; notice to board; application to qualify permit

Authority: IC 25-26-13-4
Affected: IC 25-26-13-4; IC 25-26-13-18

Sec. 1. If a qualified pharmacist, who, having upon the basis of his or her qualifications caused a pharmacy permit to be granted to any person, firm, corporation or copartnership desiring to operate, maintain, open or establish a pharmacy should leave the employ of such pharmacy, he or she shall immediately notify the Indiana board of pharmacy (board) and the owner shall file an application with the board to qualify the permit with another pharmacist.
Rule 16. New Pharmacist (Repealed)
(Repealed by Indiana Board of Pharmacy; filed Dec 3, 1985, 3:02 pm: 9 IR 771)

Rule 17. Practice of Pharmacy (Repealed)
(Repealed by Indiana Board of Pharmacy; filed Dec 3, 1985, 3:02 pm: 9 IR 771)

Rule 18. Narcotic License (Repealed)
(Repealed by Indiana Board of Pharmacy; filed Feb 11, 1981, 9:05 am: 4 IR 379)

Rule 19. Adoption by Reference of U.S. Federal Rules Pertaining to Narcotics (Repealed)
(Repealed by Indiana Board of Pharmacy; filed Feb 11, 1981, 9:05 am: 4 IR 379)

Rule 20. Violations and Penalties

856 IAC 1-20-1 Prohibitions
Authority: IC 25-26-13-4
Affected: IC 25-26; IC 35-48

Sec. 1. A pharmacist licensed to practice pharmacy under IC 25-26-13-1 through 25-26-13-29, or a pharmacist extern or a pharmacist intern licensed under IC 25-26-13-10, as a part of the responsibility, to not knowingly violate the Indiana board of pharmacy's (board's) standards for the competent practice of pharmacy shall not do the following:

(1) Violate the Uniform Indiana Controlled Substances Act found at IC 35-48-1-1 through 35-48-4-14, as amended up to and including January 1, 1983, or any of the rules promulgated by the board under the authority of the Uniform Indiana Controlled Substances Act, which were effective by January 1, 1983, insofar as such violation would pertain to the sale of drugs and devices in Indiana as defined by IC 25-26-13-2.

(2) Violate the Indiana Legend Drug Act found at IC 16-6-8-1 through 16-6-8-9 [IC 16-6 was repealed by P.L.2-1993, SECTION 209, effective July 1, 1993.], as amended up to and including January 1, 1983, insofar as such violation would pertain to the sale of drugs and devices in Indiana as defined by IC 25-26-13-2.

(3) Violate IC 16-1-30-1 through IC 16-1-30-19 [IC 16-1 was repealed by P.L.2-1993, SECTION 209, effective July 1, 1993.], as amended to and including January 1, 1983, which deal with adulterated and misbranded drugs or devices, or any rules promulgated by the board under the authority of IC 16-1-30-1 through IC 16-1-30-19 [IC 16-1 was repealed by P.L.2-1993, SECTION 209, effective July 1, 1993.], which were effective as of January 1, 1983, insofar as such violation would pertain to the sale of drugs and devices in Indiana as defined by IC 25-26-13-2.

(4) Violate 21 U.S.C. 801 through 21 U.S.C. 1191, as amended, up to January 1, 1983, which deal with drug abuse and any of the rules and regulations promulgated under the authority of said Title and Sections as of January 1, 1983, insofar as such violations would pertain to the sale of drugs and devices in Indiana as defined by IC 25-26-13-2.

(5) Violate the Federal Food, Drug, and Cosmetic Act, which is found at 21 U.S.C. 301 through 21 U.S.C. 392, as amended, up to January 1, 1983, or any rules or regulations promulgated under the authority of the said act as of January 1, 1983, insofar as such violation would pertain to the sale of drugs or devices in Indiana as defined by IC 25-26-13-2.

(6) Violate Executive Proclamations of the President of the United States, which were effective by January 1, 1983, which pertain to the sale of drugs or devices in Indiana as defined by IC 25-26-13-2.

(7) Sell, as defined in IC 25-26-13-2, controlled substances or legend drugs with or without prescription, where such sale or distribution is not in good faith and enables the person to whom the sale is made to supply or divert the controlled substances or legend drugs in an unlawful manner. The sale or distribution of controlled substances or legend drugs in unusually large amounts and within an unusually short period of time to the same individual is considered to be against the public welfare,
health and safety and may be determined to be a sale or distribution not in good faith.

(8) Sell, as defined in IC 25-26-13-2, to the public any drugs, biologicals, medicinal substances, or devices when such pharmacist knows such drugs, biologicals, medicinal substances, or devices to be forgeries or a counterfeit product or beyond the manufacturer's expiration date.

(9) Aid or abet in the practice of a pharmacy a person not having a license to practice as a pharmacist in Indiana.

(10) Practice pharmacy in such a manner as to amount to incompetency or negligence in the sale or dispensation of legend drugs as defined in the Indiana Legend Drug Act under IC 16-6-8-2 [IC 16-6 was repealed by P.L.2-1993, SECTION 209, effective July 1, 1993.] or controlled substance as defined in the Uniform Controlled Substances Act of 1973, under IC 35-48-1-1.

(11) Violate the act regulating the practice of pharmacy in Indiana, which is codified at IC 25-26-13-1 through IC 25-26-13-29 as amended up to and including January 1, 1983, or any of the rules promulgated by the board under the authority of the said act, which were effective by January 1, 1983.

Rule 21. Resale of Returned Substances

856 IAC 1-21-1 Resale of returned substances
Authority: IC 25-26-13-4
Affected: IC 25-26-13-25

Sec. 1. (a) This section implements and interprets IC 25-26-13-25(h) concerning the resale or redistribution of medications.

(b) For a medication to have been properly stored and securely maintained according to sound pharmacy practices, the storage and administration of medications in the institutional facility must be under the immediate control of licensed nursing personnel.

(c) If the medication was originally packaged by the dispensing pharmacy, it cannot be resold or redistributed unless:

1. the medication has been repackaged into unit-dose packaging using packaging materials that meets Class A or Class B standards, found in the United States Pharmacopeia (U.S.P.), page 1574, published by the United States Pharmacopeia, 22nd Revision, January 1, 1990, United States Pharmacopeia Convention, Inc., 12601 Twinbrook Parkway, Rockville, Maryland 20852, which standards are incorporated herein by reference; and

2. the repackaging process complies with the standards as found in the “Proper Treatment of Products Subjected to Additional Manipulations, Section 1191” of the United States Pharmacopeia, page 1705, 22nd Revision, 1990, which section is incorporated herein by reference.

(d) A medication repackaged under the provisions of subsection (c) shall be labeled with an expiration date of not greater than one (1) year until the manufacturer's expiration date, whichever is earlier.

Rule 22. Narcotics–Defined (Repealed)
(Repealed by Indiana Board of Pharmacy; filed Dec 3, 1985, 3:02 pm: 9 IR 771)

Rule 23. Dispensing of Dangerous Drugs

856 IAC 1-23-1 Dispensing of dangerous drugs
Authority: IC 25-26-13-4
Affected: IC 16-42-22; IC 25-26-13-4; IC 25-26-13-11

Sec. 1. In the sale or dispensing of any prescription drug or narcotic, the pharmacist shall be required to affix to the immediate container in which such prescription drug or narcotic is delivered a label bearing the following information:
(1) The name, address, and telephone number of the establishment from which such drug was sold.
(2) The date on which the prescription for such drug was filled.
(3) The number of such prescription as filed in the prescription files of the pharmacy where the prescription was filled.
(4) The name of the practitioner who prescribed such drug.
(5) The name of the patient, and if such drug was prescribed for an animal, a statement of the species of the animal and the owner's name.
(6) The directions for use of the drug as contained in the prescription.
(7) The name of the drug (trade or generic, or both) in compliance with the Generic Drug Law found in IC 16-42-22.

Rule 24. Hospital Pharmacies (Repealed)
(Repealed by Indiana Board of Pharmacy; filed Jun 8, 1982, 10:04 am: 5 IR 1420)

Rule 25. Internship for Apprentice Pharmacists (Repealed)
(Repealed by Indiana Board of Pharmacy; filed Dec 3, 1985, 3:02 pm: 9 IR 771)

Rule 26. Continuing Professional Education

856 IAC 1-26-1 Continuing professional education; general requirements; definitions
Authority: IC 25-26-13-4
Affected: IC 25-1-9-3; IC 25-26-13-14

Sec. 1. (a) The following definitions apply throughout this rule:
(1) "Continuing professional education" or "continuing education" means accredited postlicensure professional educational experience derived from participation in postgraduate studies, institutes, seminars, lectures, conferences, workshops, and such other forms of educational experiences so as to maintain the professional competency of the practice of pharmacy, improve pharmacy professional skills, and preserve pharmaceutical standards for the purpose of the protection of the health and welfare of the citizens of Indiana.
(2) "Hours" means measurement of value applied to a particular accredited continuing pharmacy educational activity as assigned by the Indiana board of pharmacy (board) relative to maintaining the competency of a pharmacist.
(3) "Contact hour" means not less than fifty (50) nor more than sixty (60) minutes of clock time participating in a continuing education program.
(4) "Continuing education unit" or "CEU" means ten (10) contact hours of continuing education credit.

(b) In order to qualify for licensure renewal, a pharmacist must meet the continuing professional education requirements as follows:
(1) Thirty (30) hours (three (3) CEUs) of continuing education as required by this rule shall be required each biennium.
(2) No hours may be carried forward from one (1) biennium to another. However, if a pharmacist fails to meet the requirements of this rule during the biennial period, the pharmacist may earn and report sufficient hours during a succeeding biennium and apply the continuing education hours retroactively to the previous biennium as if they had been earned in that previous biennium in order to qualify for renewal of the pharmacist's license. In the event a pharmacist applies credits to a previous biennium for the reasons stated in this section, those credits may not be used for any other biennium.
(3) All continuing education program hours from sponsors not approved by ACPE must be evaluated and accepted by the board.
(4) Continuing education biennium shall be that time period consisting of January 1 of all even-numbered years through December 31 of the following odd-numbered year.
(c) Accredited continuing education hours may be compiled in the following ways if the sponsor grants the participant a certificate of completion:
   (1) Cassette and audio-visual presentation.
   (2) In-company professional seminars.
   (3) Accredited school of pharmacy continuing education programs.
   (4) Postgraduate courses in pharmaceutical sciences.
   (5) Correspondence courses.
   (6) Programs granted continuing education credit by other states.
   (7) Continuing education television series.
   (8) Programs sponsored by professional groups in public health provider services.
   (9) Professional society and association sponsored program.
   (10) Approved business, management, and computer courses.
   (11) Programs of sponsors approved by ACPE.

(d) Accredited continuing education hours may be compiled from other programs and experiences if they are evaluated and accepted by the board as meeting the definition of continuing professional education as found in subsection (a)(1).

(e) As provided in subsection (b)(3), continuing education sponsors (hereinafter referred to as sponsors) are responsible for submitting continuing education programs to the board for approval in addition to the following:
   (1) A sponsor shall be any person, school, association, or corporation who develops a continuing education program.
   (2) The continuing education program must receive approval of the board for final acceptance.
   (3) If a sponsor wishes to notify prospective participants in advance of the value (in hours or in CEUs) of a program, the content of the program shall be submitted to the board for evaluation. If the sponsor does not submit the content for evaluation, the sponsor shall note in all material relevant to the program that it has not been evaluated and the hours of credit listed are subject to review by the board.
   (4) Sponsors shall receive written notice from the board for approval or disapproval from the board. Approved programs shall be given an identification number stating the year and hourly value.
   (5) Program changes must be made to and accepted by the board or the evaluation and acceptance of the program becomes null and void.
   (6) Continuing education credit may be granted only once for each program to any individual participant.
   (7) Any member of the board shall have the right to attend and participate in any continuing education program.
   (8) Programs may be evaluated after presentation or participation if a written request is made to the board within ninety (90) days of the date of presentation.
   (9) Sponsors shall retain a file of participants' program completion for four (4) years.
   (10) When applying to the board for credit, sponsors shall supply the following information on the application for continuing education course approval, supplied by the board:
       (A) Name and address of applicant.
       (B) Program title.
       (C) Location, date, and time of program.
       (D) Sponsoring organization.
       (E) Type of program.
       (F) Name and qualification of each speaker.
       (G) Three (3) learning objectives for the program.
       (H) Contact hours of the course.
       (I) Method for evaluating the program.

(f) Pharmacists licensed with the board (hereinafter called participants) have the following responsibilities:
   (1) Obtain a minimum of thirty (30) hours of continuing education per biennium unless first licensed during the biennium which would make those newly licensed individuals subject to subdivision (5):
       (A) a maximum of one-fifth (1/5) of the total hours may be business, management, or computer courses;
       (B) at least four-fifths (4/5) of the total hours must be pharmacy practice related; and
       (C) at least one-half (1/2) of the total hours must be provided by sponsors approved by ACPE.
   (2) Report program name, identification number, and approved hours of continuing education to the board at the time of license
renewal.
(3) Retain a file of certificates of completion for four (4) years from the end of the biennium for which the continuing education applied in order to provide copies of certificates upon request for the board's periodic audit of continuing education compliance.
(4) Earn one and one-fourth (1.25) hours of continuing education credit for each month or part of a month from date of licensure until the end of the biennium in which licensure originates if the pharmacist becomes licensed during the biennium. However, a pharmacist who becomes newly licensed for the first time in any state in the last six (6) months of the biennium shall not be required to complete any continuing education for the biennium.
(5) Continuing education hours may be transferred from another state to Indiana if the transfer state recognizes Indiana continuing education hours.
(g) Failure to comply with any one (1) or all of the provisions of this rule while continuing to hold a license as a pharmacist in Indiana shall constitute professional incompetence by failing to keep abreast of current professional theory or practice under IC 25-1-9-3(a)(4)(B) and the pharmacist is subject to discipline under IC 25-1-9. *(Indiana Board of Pharmacy: Reg 29; filed Mar 1, 1974, 3:05 p.m.: Rules and Regs. 1975, p. 516; filed Oct 26, 1984, 3:26 p.m.: 8 IR 212; filed Jan 21, 1994, 3:00 p.m.: 17 IR 1096, eff Jan 1, 1994 [IC 4-22-2-36 suspends the effectiveness of a rule document for thirty (30) days after filing with the secretary of state. LSA Document #93-152 was filed Jan 21, 1994.]; readopted filed Dec 2, 2001, 12:35 p.m.: 25 IR 1335; readopted filed Sep 26, 2008, 10:35 a.m.: 20081015-IR-856080346RFA; readopted filed Dec 1, 2014, 8:33 a.m.: 20141231-IR-856140392RFA; readopted filed Oct 6, 2020, 12:03 p.m.: 20201104-IR-856200443RFA)*

Rule 27. Fee Structure

856 IAC 1-27-1 Fees
Authority: IC 25-1-8-2; IC 25-26-13-4
Affected: IC 25-26-13

Sec. 1. (a) The following fees apply to an applicant for licensure to practice as a pharmacist:
(1) Application for examination for a pharmacist's license $100
(2) Reexamination of the jurisprudence examination $25
(3) Reexamination of the practical examination $25
(4) Licensure by reciprocity (license transfer) $100
(5) Application for the renewal of a biennial license $160
(6) Certification of qualifications, grades, or registration to another state $10
(7) Wall certificate $10
(8) Duplicate pharmacist pocket license No fee
(9) Compilation of pharmacy laws $10
(b) The following fees apply to an applicant for permission to operate, maintain, open, or establish a pharmacy:
(1) Initial application $100
(2) Application for renewal of biennial license $200
(3) Application for change of ownership $50
(4) Application for change of location $50
(5) Application for remodel $50
(6) Duplicate pharmacy permit No fee
(7) Nonresident pharmacy initial application $100
(8) Application for renewal of nonresident pharmacy biennial license $200
(c) The following fees apply to applicants for permits or certifications authorized by the board:
(1) Intern/extern initial application $10
(2) Intern/extern annual renewal $10
(3) Pharmacy technician initial application $25
(4) Pharmacy technician biennial renewal $25
*(Indiana Board of Pharmacy: Reg 29; filed Aug 30, 1977, 8:25 a.m.: Rules and Regs. 1978, p. 660; filed Mar 5, 1985, 2:42 p.m.)*
Rule 28. Institutional Pharmacies (Repealed)
(Repealed by Indiana Board of Pharmacy; filed Dec 26, 2001, 2:44 p.m.: 25 IR 1643)

Rule 28.1. Institutional Pharmacies and Pharmacy Services

856 IAC 1-28.1-1 Definitions

Authority: IC 25-26-13-4
Affected: IC 16-42-19-5; IC 25-26-13

Sec. 1. In addition to the definitions in IC 25-26-13-2 and for purposes of this rule, the following definitions apply throughout this rule:

1) "Cabinet" includes a mechanical storage device for dispensing drugs. The term means a locked or secured enclosure located outside the pharmacy licensed area:
   (A) to which only specifically authorized personnel may obtain access by key or combination available only to those authorized persons by:
      (i) security code;
      (ii) password; or
      (iii) other method of positively identifying an individual; and
   (B) that is sufficiently secure to deny access to unauthorized persons.

2) "Cognitive services" means those acts and operations related to a patient's drug therapy that are judgmental in nature, based on knowledge, and derived from empirical factual information.

3) "Consultant pharmacist" means a pharmacist licensed pursuant to IC 25-26-13-11 and who engages in the practice of pharmacy in or for long term care facility or other residential patients, other than as a supplying pharmacist.

4) "Consulting" means the provision of nonsupply related cognitive services that include, but are not necessarily limited to, the following:
   (A) Drug regimen review as defined in IC 25-26-13-2.
   (B) Provision of advice and counsel on drugs, the selection and use thereof to the facility, the patients therein, the health care providers of the facility regarding the appropriateness, use, storage, handling, administration, and disposal of drugs within the facility.
   (C) Participation in the development of policies and procedures for drug therapy within the institution, including storage, handling, administration, and disposing of drugs and devices.
   (D) Assuring the compliance with all applicable laws, rules, and regulations.
   (E) Provision of educational and drug information sources for the education and training of the facility health care professionals.
   (F) Accepting responsibility for the implementation and performance of review of quality-related or sentinel events as defined in this rule.

5) "Emergency drugs" means those drugs that:
   (A) may be required to meet the immediate therapeutic needs of patients; and
   (B) are not available from any other authorized source in sufficient time to prevent risk of harm to patients by delay resulting from obtaining such drugs from other sources.

6) "Institutional facility" means any health care facility whose primary purpose is to provide a physical environment for patients to obtain health care services, except those places where practitioners, as defined by IC 16-42-19-5, who are duly licensed, engage in private practice and pharmacies licensed under IC 25-26-13-17.

7) "Institutional pharmacy" means that portion of an institutional facility where pharmacy is practiced and is:
(A) the location of the selection, compounding, production, sale, storage, and distribution of drugs, devices, and investigational or new drugs used in the diagnosis and treatment of injury, illness, and disease pursuant to drug orders and prescriptions by practitioners; and
(B) licensed with the board under IC 25-6-3-7.

(8) "Performance improvement program" means a continuous, systematic review of key medication use processes to identify, evaluate, and improve medication use and patient care.

(9) "Pharmacist in charge" (by whatever title, for example, "pharmacy manager", "pharmacy director", or "director of pharmacy") means the pharmacist who directs the activities of the institutional pharmacy and who is, as such, responsible for:
(A) all activities of the institutional pharmacy; and
(B) meeting the requirements of:
(i) IC 25-26-13;
(ii) the rules of the board; and
(iii) any federal requirements pertaining to institutional pharmacies.

The qualifying pharmacist may, depending on the circumstances, also be the pharmacist in charge, though the pharmacist in charge is not required to be the qualifying pharmacist.

(10) "Policy and procedure manual" means a written document containing the agreed-to institutional rules of operation and methodology for the effective delivery of pharmacy services.

(11) "Qualifying pharmacist" means the pharmacist who accepts responsibility for the operation of a pharmacy as defined in IC 25-26-13-2 and whose name is listed on the pharmacy permit granted under IC 25-26-13-17.

(12) "Quality-related event" means the inappropriate provision of pharmaceutical services whether or not resulting in an adverse health incident, including the following:
(A) A variation from the practitioner's order, including, but not limited to, the following:
(i) Dispensing an incorrect drug.
(ii) Dispensing an incorrect drug strength.
(iii) Dispensing an incorrect dosage form.
(iv) Dispensing a drug to a wrong patient.
(v) Providing inadequate or incorrect packaging, labeling, or directions.
(vi) Failing to provide an ordered drug.
(B) A failure to identify and manage:
(i) overutilization or underutilization;
(ii) therapeutic duplication;
(iii) drug-disease contraindications;
(iv) drug-drug interactions;
(v) incorrect drug dosage or duration of therapy;
(vi) drug-allergy interactions; or
(vii) clinical abuse and/or misuse.

(13) "Reversible condition" means a condition that requires intervention to resolve in a reasonable time.

(14) "Sentinel event" means an unexpected occurrence involving serious adverse effect, such as disability, life threatening condition, prolonged hospitalization, or death in a patient resulting from medication use.

(15) "Supplying pharmacist" means that pharmacist licensed in the state where the pharmacist is practicing and who is practicing in a supplying pharmacy (as defined in this rule) and who accepts responsibility for all aspects the drugs and devices sold (as defined in IC 25-26-13-2) or dispensed to a facility.

(16) "Supplying pharmacy" means a pharmacy licensed in the state where the pharmacy is located and which provides drugs and devices to patients in long term care or other facilities where patients reside.

(17) "Temporary condition" means a condition that resolves in a reasonable time without intervention.

(Indiana Board of Pharmacy; 856 IAC 1-28.1-1; filed Dec 26, 2001, 2:44 p.m.: 25 IR 1636; readopted filed Sep 26, 2008, 10:55 a.m.: 20081015-IR-856080346RFA; readopted filed Dec 1, 2014, 8:33 a.m.: 20141231-IR-856140392RFA; readopted filed Oct 6, 2020, 12:03 p.m.: 20201104-IR-856200443RFA)
856 IAC 1-28.1-2 Purpose
Authority: IC 25-26-13-4
Affected: IC 25-26-13-17

Sec. 2. The purpose of this rule is to set forth the responsibilities of pharmacists and pharmacies serving institutional and home health care patients. (Indiana Board of Pharmacy; 856 IAC 1-28.1-2; filed Dec 26, 2001, 2:44 p.m.: 25 IR 1637; readopted filed Sep 26, 2008, 10:55 a.m.: 20081015-IR-856080346RFA; readopted filed Dec 1, 2014, 8:33 a.m.: 20141231-IR-856140392RFA; readopted filed Oct 6, 2020, 12:03 p.m.: 20201104-IR-856200443RFA)

856 IAC 1-28.1-3 Applicability
Authority: IC 25-26-13-4
Affected: IC 25-26-13-17

Sec. 3. This rule is applicable to pharmacies located:
(1) within institutional facilities as defined in section 1 of this rule and classified as Type II pharmacies in IC 25-26-13-17;
and
(2) outside institutional facilities that serve institutionalized patients who are classified as Type III and Type VI pharmacies as in IC 25-26-13-17. (Indiana Board of Pharmacy; 856 IAC 1-28.1-3; filed Dec 26, 2001, 2:44 p.m.: 25 IR 1637; readopted filed Sep 26, 2008, 10:55 a.m.: 20081015-IR-856080346RFA; readopted filed Dec 1, 2014, 8:33 a.m.: 20141231-IR-856140392RFA; readopted filed Oct 6, 2020, 12:03 p.m.: 20201104-IR-856200443RFA)

856 IAC 1-28.1-4 Pharmacist in charge; responsibilities
Authority: IC 25-26-13-4
Affected: IC 25-26-13-17

Sec. 4. The pharmacist in charge or an appropriate designee shall:
(1) be responsible for establishing and carrying out a performance improvement program as defined in section 1 of this rule;
and
(2) develop or be responsible for development of a policies and procedures manual that shall be of sufficient scope and detail that pharmacists practicing in the institutional pharmacy will be able to practice effectively and safely. (Indiana Board of Pharmacy; 856 IAC 1-28.1-4; filed Dec 26, 2001, 2:44 p.m.: 25 IR 1637; readopted filed Sep 26, 2008, 10:55 a.m.: 20081015-IR-856080346RFA; readopted filed Dec 1, 2014, 8:33 a.m.: 20141231-IR-856140392RFA; readopted filed Oct 6, 2020, 12:03 p.m.: 20201104-IR-856200443RFA)

856 IAC 1-28.1-5 Policies and procedures manual
Authority: IC 25-26-13-4
Affected: IC 25-26-13-17

Sec. 5. (a) The pharmacist in charge shall develop or be responsible for the development of a policies and procedures manual that shall be of sufficient scope and detail that pharmacists practicing in the institutional pharmacy will be able to practice effectively and safely.
(b) The manual required in this section shall be available for inspection by a member of the board or its representative.
(c) The policies and procedures manual shall contain, at a minimum, the following:
(1) Provisions for a continuous quality improvement committee that shall be comprised of staff members of the pharmacy, including, but not necessarily limited to, the following:
(A) Pharmacists.
(B) Pharmacist interns or externs.
(C) Pharmacy technicians.
(D) Clerical or support staff.
(E) Other persons deemed necessary by the qualifying pharmacist.

(2) Provisions for the pharmacist in charge or designee to ensure that the committee conducts a review of quality related events at least every three (3) months.

(3) A process to record, measure, assess, and improve quality of patient care.

(4) The procedure for reviewing quality related or sentinel events.

856 IAC 1-28.1-6 Personnel
Authority: IC 25-26-13-4
Affected: IC 25-26-13-17

Sec. 6. The qualifying pharmacist and/or the pharmacist in charge shall develop and implement, or cause to be developed and implemented, policies and procedures that specify duties to be performed by pharmacy technicians and other ancillary personnel.

856 IAC 1-28.1-7 Pharmacist's duties
Authority: IC 25-26-13-4
Affected: IC 16-42-19-3; IC 25-26-13-2; IC 25-26-13-31; IC 25-26-16

Sec. 7. (a) Pursuant to authority granted in IC 25-26-13-2 and IC 25-26-13-31, the duties of the pharmacists practicing in the institutional pharmacy include, but are not limited to, the requirements in this section.

(b) The pharmacist practicing in an institutional pharmacy shall, at a minimum, do the following:

(1) Obtain and maintain patient drug histories and drug profiles.

(2) Perform drug evaluations, drug utilization review, drug regimen review, and drug therapy management under protocol approved by the medical staff of the institution and authorized by IC 25-26-16.

(3) Interpret the drug order written by a practitioner in or transmitted to an institutional facility and either received in or subsequently transmitted to the pharmacy.

(4) Be responsible for checking all drug orders within a maximum of twenty-four (24) hours, including those written during periods when the pharmacy is closed and orders are filled from sources, including emergency kits, drug cabinets, or the pharmacy as authorized under section 8(c) of this rule.

(5) Be responsible for drug product selection of the item that will be used to fill the drug order that may be established either by policy or formulary pursuant to the institution's pharmacy and therapeutics committee or related committee.

(6) Be responsible for determining the legality, completeness, and appropriateness of the drug order and product pursuant to IC 16-42-19-3.

(7) Participate in drug or drug-related research.

(8) Provide counseling, advising, and education of patients, patients' care givers, and health care providers and professionals on issues regarding drugs or drug therapy.

(9) Compound, label, administer, and dispense drugs or devices.

(10) Assess, record, and report quality related events as defined in this rule.

(11) Be responsible for storage and distribution of drugs and devices.

(12) Provide documentation in the medical record of the recommendations made related to the patient's therapeutic response to medication.

(13) Any other duties that shall from time to time be necessary for the proper operation of the institutional pharmacy.

(c) The consultant pharmacist shall, in addition to the duties in subsection (b), provide cognitive services as defined in this rule, including, at a minimum, the following:

(1) Drug regimen reviews as defined in IC 25-26-13-2.
(2) Offer advice and counsel to other health care providers as deemed appropriate regarding the pharmaceutical care of the patient.
(3) Develop or assist in the development of policies and procedures for the legal, safe, and effective means of handling, storing, and disposing of drugs and devices.
(4) Be responsible for assuring the safe and appropriate receipt, labeling, storage, and disposal of all drugs placed outside the pharmacy licensed area in emergency drug kits or other storage devices as authorized by law or rule.

Indiana Administrative Code Page 22
856 IAC 1-28.1-9 Emergency drug kits from Type III and Type VI pharmacies

Authority: IC 25-26-13-4
Affected: IC 25-26-13-17; IC 35-38

Sec. 9. (a) Emergency drug kits supplied by pharmacies with a Type III or Type VI permit shall be in compliance with this section.

(b) All drugs in the emergency kit shall be provided and owned by a single supplying pharmacy.

(c) All drugs in the emergency drug kit shall be selected and approved by a committee whose membership includes, at a minimum, the following:
   (1) The facility's consultant pharmacist.
   (2) A licensed nurse.
   (3) A physician (medical doctor or doctor of osteopathy).
   (4) The facility administrator.

(d) The selection process must identify drugs and quantities thereof in the emergency drug kit.

(e) The lists of drugs and quantities included in the emergency drug kit shall be reviewed as required periodically, but no less often than yearly.

(f) Labeling as follows:
   (1) The exterior labeling of the emergency drug kit as described in this subsection shall contain, at a minimum, the following:
      (A) Drug name (trade name, generic name, or active ingredients).
      (B) Drug strength or size, if any.
      (C) Quantity included therein.
      (D) Expiration date of the kit as defined in this section.
   (2) All drugs contained in the emergency drug kit as described in this section shall be labeled, at a minimum, with the following:
      (A) Drug name (trade name, generic name, or active ingredients).
      (B) Drug strength or size, if applicable.
      (C) Name of the manufacturer, packer, or distributor.
      (D) Lot number.
      (E) Expiration date.

(g) The expiration date of the emergency drug kit, as required in subsection (f)(1)(D) shall be the earliest date of expiration of any of the drugs included in the kit at any time.

(h) All emergency kits subject to this subsection:
   (1) shall be stored in a secure area, suitable for the prevention of unauthorized access to or diversion of the drugs therein;
   (2) if controlled substances, as defined in IC 35-38, are stored in such a manner as to facilitate periodic reconciliation by the facility nursing staff, that reconciliation shall be recorded in an appropriate manner as determined by the committee described under this section; and
   (3) all controlled substances contained in emergency drug kits shall remain the property of the supplying pharmacy and as such shall be included in the pharmacy's biennial inventory as required by 21 CFR 1303.04 and 21 CFR 1301.11.

(i) The nurse responsible for removing drugs from an emergency drug kit shall record or cause to be recorded, in a manner designated under subsection (h)(2), the following minimum information:
   (1) Name of the patient.
   (2) Name of the drug.
   (3) Strength of the drug.
   (4) Quantity removed.
   (5) Date of removal.
   (6) Time of removal.

(j) Removal of a controlled substance in Schedule II pursuant to an oral authorization from a practitioner shall be documented, and the nurse accepting such authorization is responsible for compliance with 856 IAC 2-6-7 regarding prescription requirements for controlled substances in Schedule II.

(k) Removal of a controlled substance in Schedule III, IV, or V, pursuant to an oral authorization from a practitioner, shall be
documented, and the nurse accepting such authorization is responsible for compliance with 856 IAC 2-6-12.

(l) Whenever an emergency kit is opened, for any reason, the supplying pharmacy shall be notified in a timely manner, and the pharmacy shall restock, if necessary, and resell the kit promptly so as to prevent risk of harm to patients of the facility. (Indiana Board of Pharmacy; 856 IAC 1-28.1-9; filed Dec 26, 2001, 2:44 p.m.: 25 IR 1639; readopted filed Sep 26, 2008, 10:55 a.m.: 20081015-IR-856080346RFA; readopted filed Dec 1, 2014, 8:33 a.m.: 20141231-IR-856140392RFA; readopted filed Oct 6, 2020, 12:03 p.m.: 20201104-IR-856200443RFA)

856 IAC 1-28.1-10 Security
Authority: IC 25-26-13-4
Affected: IC 25-26-13-17

Sec. 10. The pharmacy shall be capable of being secured against entry by key, combination, code, password, or other method developed that can positively identify an individual so as to prevent access by unauthorized personnel. (Indiana Board of Pharmacy; 856 IAC 1-28.1-10; filed Dec 26, 2001, 2:44 p.m.: 25 IR 1640; readopted filed Sep 26, 2008, 10:55 a.m.: 20081015-IR-856080346RFA; readopted filed Dec 1, 2014, 8:33 a.m.: 20141231-IR-856140392RFA; readopted filed Oct 6, 2020, 12:03 p.m.: 20201104-IR-856200443RFA)

856 IAC 1-28.1-11 Performance improvement events, sentinel events, corrective and avoidance measures, review, records, and documentation
Authority: IC 25-26-13-4
Affected: IC 25-26-13-17

Sec. 11. (a) The pharmacist in charge shall, as a part of the pharmacy's performance improvement program, assure or be responsible for assuring that data are collected to:

(1) monitor the stability of existing medication use processes;
(2) identify opportunities for improvement; and
(3) identify changes that will lead to and sustain improvement.

(b) Identification of quality related or sentinel event as defined in section 1 of this rule shall be cause for:

(1) an intensive analysis of causal factors involved in the event; and
(2) plans for corrective actions.

(c) Records of all processes, analysis, and corrective measures instituted involving such pharmacy quality related or sentinel event shall be maintained for a period of not less than two (2) years.

(d) The committee created under section 5(c)(1) of this rule shall, at a minimum, consider the effects on quality of the pharmacy system due to the following:

(1) Staffing levels of both professional and technical personnel.
(2) Workflow.
(3) Use of technology.
(e) Requirements for documentation of performance improvement monitoring of medication use processes, confidentiality of records, summarization, and examination by the board shall be as follows:

(1) Each quality related or sentinel event that occurs, or is alleged to have occurred, as the result of activities involving pharmacy operations, shall be documented in a written or electronic storage record created solely for that purpose.
(2) The quality related or sentinel event shall be:
   (A) initially documented by the pharmacist to whom it is first described; and
   (B) recorded on the same day of its having been so described to the pharmacist.
(3) Documentation shall include a description of the event that is of sufficient detail to permit analysis of the event.
(4) The pharmacist in charge shall summarize, or cause to be summarized, efforts to improve the medication use process on a semiannual basis.
(5) No patient names or employee names shall be included in this summary report.
(6) This report shall be maintained for a period of not less than two (2) years.
(7) The records created and maintained as a component of a pharmacy performance improvement program are confidential
to the extent law permits. However, to assure compliance, the board or its representative may review the policies and procedures manual and a summarization of events described in subsection (b).

(Indiana Board of Pharmacy; 856 IAC 1-28.1-11; filed Dec 26, 2001, 2:44 p.m.: 25 IR 1640; readopted filed Sep 26, 2008, 10:55 a.m.: 20081015-IR-856080346RFA; readopted filed Dec 1, 2014, 8:33 a.m.: 20141231-IR-856140392RFA; readopted filed Oct 6, 2020, 12:03 p.m.: 20201104-IR-856200443RFA)

856 IAC 1-28.1-12 Drug distribution, storage, and accountability

Sec. 12. (a) All drugs and devices in pharmacies located within institutions shall be obtained and used in accordance with written policies and procedures that have been prepared or approved by the qualifying pharmacist or pharmacist in charge and the medical staff who explain the:

(1) selection;
(2) distribution;
(3) storage; and
(4) safe and effective use of:
   (A) drugs;
   (B) new drugs;
   (C) investigational new drugs; and
   (D) devices;

in the facility.

(b) The pharmacist in charge of the pharmacy located within an institution shall be responsible for the following:

(1) The safe and efficient:
   (A) distribution;
   (B) control;
   (C) storage; and
   (D) accountability;

for all drugs and devices.

(2) The compliance with all applicable Indiana and federal laws and rules.

(c) Labeling requirements are as follows:

(1) All drugs, other than unit-of-use packages, dispensed by an institutional pharmacy, intended for use within the facility, shall be distributed in appropriate containers and adequately labeled so as to identify, at a minimum, the following:
   (A) Patient identification.
   (B) Brand name or generic name, or both.
   (C) Strength, if applicable.
   (D) Route of administration.
   (E) Quantity.
   (F) Pharmacist's initials.
   (G) Location of the patient within the institution.

(2) Unit-of-use packages shall contain information to adequately label them, at a minimum, as follows:
   (A) Drug name (brand or generic, or both).
   (B) Strength, if applicable.
   (C) Control number and/or expiration date.

(3) All drugs dispensed by an institutional pharmacy to patients about to be discharged, or temporarily discharged, from institutions with Type III or Type IV permits, shall be labeled with the following minimum information:
   (A) Name, address, and telephone number of the institutional pharmacy.
   (B) Date and identifying serial number.
   (C) Name of patient.
   (D) Name of drug and strength, if applicable.
(E) Directions for use by the patient and route of administration.
(F) Name of prescribing practitioner.
(G) Precautionary information if any contained in the prescription.

(d) Requirements for the disposition of discontinued or recalled drugs are as follows:
(1) The qualifying pharmacist or pharmacist in charge shall be responsible for the development and implementation of policies and procedures for the return to the pharmacy of drugs and containers that are:
   (A) discontinued, outdated, or recalled; or
   (B) in containers with worn, illegible, or missing labels;
for proper disposition.
(2) The qualifying pharmacist or pharmacist in charge or his or her designee shall make proper disposition of such drugs at the storage site.
(e) The qualifying pharmacist or pharmacist in charge shall ensure that drugs are dispensed from the institutional pharmacy only upon authorized practitioner's:
   (1) written orders;
   (2) direct copies;
   (3) facsimiles thereof; or
   (4) electronically transmitted by other means and printed or displayed appropriately.
(f) Accountability requirements are as follows:
(1) The qualifying pharmacist or pharmacist in charge of an institutional pharmacy shall ensure that policies and procedures documenting the trail of:
   (A) controlled substances; and
   (B) such other drugs as may be specified by the appropriate committee of the institutional facility, from ordering and receiving by the pharmacy through administration or wastage of drug at the patient level.
(2) The qualifying pharmacist or pharmacist in charge shall be responsible for review of this process on a continual basis by review of:
   (A) proofs-of-use documentation; or
   (B) other electronic documentation methodology.
(3) At a minimum, the documentation process shall be able to identify the following:
   (A) The name of the drug.
   (B) The dose.
   (C) The patient's name.
   (D) The date and time of administration to the patient.
   (E) The identification of the individual administering.
   (F) The record of aliquot portion destroyed, if any, and identification of witness.

(g) All records and reports that are required for pharmacy functions shall be maintained according to policies and procedures developed within the institution with the approval of the pharmacist in charge for a period of not less than two (2) years. (Indiana Board of Pharmacy; 856 IAC 1-28.1-12; filed Dec 26, 2001, 2:44 p.m.: 25 IR 1641; readopted filed Sep 26, 2008, 10:55 a.m.: 20081015-IR-856080346RFA; readopted filed Dec 1, 2014, 8:33 a.m.: 20141231-IR-856140392RFA; readopted filed Oct 6, 2020, 12:03 p.m.: 20201104-IR-856200443RFA)

856 IAC 1-28.1-13 Drug self-administration

Authority: IC 25-26-13-4
Affectec: IC 25-26-13-17

Sec. 13. Self-administration of drugs by patients of an institutional facility shall be permitted only if such use is specifically authorized by the treating or ordering physician and:
(1) the patient's knowledge of self-administration has been evaluated; or
(2) the patient has received training in the proper manner of self-administration:
   (A) by a pharmacist; or
   (B) according to hospital policy; and
there is no risk of harm to the patient. (Indiana Board of Pharmacy; 856 IAC 1-28.1-13; filed Dec 26, 2001, 2:44 p.m.: 25 IR 1642; readopted filed Sep 26, 2008, 10:55 a.m.: 20081015-IR-856080346RFA; readopted filed Dec 1, 2014, 8:33 a.m.: 20141231-IR-856140392RFA; readopted filed Oct 6, 2020, 12:03 p.m.: 20201104-IR-856200443RFA)

856 IAC 1-28.1-14 Patient's own medication
  Authority:  IC 25-26-13-4
  Affected:  IC 25-26-13-17

Sec. 14. (a) An institutional pharmacy is prohibited from accepting and dispensing drugs that are brought into the institution by the patient, even if intended for use by that same patient. However, use of the patient's own medication may be permitted if:
   (1) the patient or the patient's representative may maintain the patient's own medication:
      (A) at the bedside; or
      (B) for drugs with special storage requirements, including, but not limited to, refrigeration in an appropriate storage area in the patient care area under control of nursing personnel for appropriate administration to that patient only; and
   (2) the nurses in charge of that patient's care shall witness the administration and maintain records of such use.
   (b) If the patient or the patient's representative brings in medication part or all of which is still present at such time a patient expires, those drugs shall be delivered to the institutional pharmacy for appropriate destruction. Such drugs may not be turned over to the patient's representatives. This rule shall be made clear to the parties involved prior to the permission to use such medication. Patients who are discharged shall take with them their own medications brought to the institution under the terms of this section.
   (c) In the event the patient is discharged and leaves drugs brought in under this section, either deliberately or inadvertently, such drugs shall be documented and stored at the appropriate nursing location for a maximum of seven (7) calendar days. If not claimed by the patient or the patient's agent within those seven (7) calendar days, the drugs so stored shall be destroyed as described in subsection (b). (Indiana Board of Pharmacy; 856 IAC 1-28.1-14; filed Dec 26, 2001, 2:44 p.m.: 25 IR 1642; readopted filed Sep 26, 2008, 10:55 a.m.: 20081015-IR-856080346RFA; readopted filed Dec 1, 2014, 8:33 a.m.: 20141231-IR-856140392RFA; readopted filed Oct 6, 2020, 12:03 p.m.: 20201104-IR-856200443RFA)

856 IAC 1-28.1-15 Inspections
  Authority:  IC 25-26-13-4
  Affected:  IC 16-42-3-3; IC 25-26-13-17

Sec. 15. The qualifying pharmacist or pharmacist in charge shall be responsible for the timely inspection of all areas where drugs are stored, used, or administered. The inspection can be carried out by qualified designee and appropriate records kept. The inspection shall verify, at a minimum, the following:
   (1) Disinfectants and drugs solely for nontherapeutic external use are stored separately and apart from drugs for internal use or injection.
   (2) Drugs requiring special storage conditions are appropriately stored to assure the drugs are not adulterated as described in IC 16-42-3-3.
   (3) Drugs subject to deterioration are removed from any accessible location prior to the expiration date (manufacturer's or other such as required under 856 IAC 1-21) and disposed of appropriately.
   (4) Emergency drugs designated by the institution are in adequate supply and are properly stored in the institution.
   (5) All necessary and required security and storage standards are met.
   (6) All pharmacy-related policies and procedures of the institution are complied with. (Indiana Board of Pharmacy; 856 IAC 1-28.1-15; filed Dec 26, 2001, 2:44 p.m.: 25 IR 1642; readopted filed Sep 26, 2008, 10:55 a.m.: 20081015-IR-856080346RFA; readopted filed Dec 1, 2014, 8:33 a.m.: 20141231-IR-856140392RFA; readopted filed Oct 6, 2020, 12:03 p.m.: 20201104-IR-856200443RFA)

Rule 29. Electronic Data Processing of Prescriptions
Sec. 1. (a) No electronic data processing system may be used by a pharmacist pursuant to a category I or category III pharmacy permit as an alternative to his or her recording of prescription information unless that system has been approved by the board.

(b) No electronic data processing system may be used by a pharmacist as an alternative to his or her recording of information directly on the original prescription under IC 25-26-13-25(e), without the approval of the board, and such an electronic data processing system does not qualify for approval unless it satisfies at a minimum the requirements found in this rule. Any such system must be approved by the board before initial installation in Indiana. Any pharmacy installing such a system must make a written request to the board for approval. Approval is subject to withdrawal for cause so that the pharmacist must in such a case discontinue use of the system as an alternative. (Indiana Board of Pharmacy; 856 IAC 1-29-1; filed Aug 16, 1984, 3:55 p.m.; 7 IR 2543; readopted filed Dec 2, 2001, 12:35 p.m.; 25 IR 1337; readopted filed Oct 4, 2007, 3:33 p.m.; 20071031-IR-856070060RFA; filed Jun 19, 2013, 10:06 a.m.; 20130717-IR-856120619FRA; readopted filed Nov 25, 2013, 9:24 a.m.; 20131225-IR-856130308RFA; errata filed Jun 16, 2017, 2:45 p.m.; 20170705-IR-856170297ACA; readopted filed Nov 18, 2019, 11:41 a.m.; 20191218-IR-856190076RFA)

Sec. 2. (a) Any such proposed computerized system must provide on-line retrieval (via visual display device or hard-copy printout) of original prescription order information for those prescription orders which are currently authorized for refilling. This shall include:

1. prescription number;
2. date of issuance of the original prescription order by the prescriber;
3. full name and address of the patient;
4. name and address of prescriber;
5. DEA number of prescriber when drug prescribed is controlled substance;
6. the name, strength (if applicable), dosage form, and quantity of medication originally dispensed;
7. total number of refills authorized by prescriber.

(b) In addition to the information contained in subsection (a) above, the following information shall be maintained for each filling:

1. date dispensed;
2. quantity dispensed, if different from the quantity prescribed;
3. identification of dispensing pharmacist;
4. adequate information to determine the number of authorized refills remaining.

(c) The system shall be able to produce a complete printout of current prescription status that would provide all necessary refill information for use in the event that the pharmacy wishes to discontinue use of the computer system. The report shall list all currently refillable prescriptions in sequence by prescription number. The following information shall be included:

1. prescription number;
2. date dispensed, quantity, and pharmacist's identification;
3. the number of refills presently remaining and the amount owed, if any, from any partial refills. (Indiana Board of Pharmacy; 856 IAC 1-29-2; filed Aug 16, 1984, 3:55 pm; 7 IR 2544; readopted filed Nov 13, 2001, 3:55 p.m.; 25 IR 1330; readopted filed Oct 4, 2007, 3:33 p.m.; 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.; 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.; 20191218-IR-856190076RFA)

Sec. 3. Hard copy of daily dispensing; verification and retention; back-up capability

Authority: IC 25-26-13-4
Affected: IC 25-26-13-25
Sec. 3. (a) A pharmacy using an electronic data processing system must provide a separate hard copy printout of prescription or drug order and refill data for each day's dispensing or other board approved uniformly maintained readily retrievable system. This hard copy printout or other board approved system shall include the following:

1. Prescription number.
2. Date of dispensing.
3. Patient name.
4. Drug and strength (if applicable).
5. Quantity dispensed.
7. Pharmacist identification.
8. Refill status.

(b) The dispensing pharmacist must verify that the data is correct to the best of his or her knowledge and date and sign the document or log book in the same manner as he or she would sign a check or legal document.

(c) This documentation shall be maintained for a period of two (2) years from the dispensing date. The daily hard copy printout may be replaced with a monthly printout or other permanent documentation containing the same information.

(d) Each system must have the capability of informational backup and such documentation must be stored in a secure location.

(e) If the electronic data processing system can capture an unalterable and legible digital image of the prescription or drug order, the digital image may be considered the original prescription record as follows:

1. A prescription that is stored as a digital image must have any notes of clarification or alterations, or both, recorded as an electronic annotation on the digital image of the prescription.
2. As used in this section, "digital image" means the electronic record produced through the process of imaging, whereby a hard copy prescription is scanned by a computer and converted from a human-readable format to a computer-readable, digital format that can be used in an electronic data processing system.
3. As used in this section, "electronic annotation" means a means by which to mark up a digital image so as to allow notes or clarification, or both, to be added to the prescription record without altering the original digital image.

(f) The electronic data processing system must be capable of maintaining, printing, and providing, upon a request by the board or the board's compliance officers, all of the prescription information required by state law and regulations of the board within seventy-two (72) hours of the request. (Indiana Board of Pharmacy; 856 IAC 1-29-3; filed Aug 16, 1984, 3:55 p.m.: 7 IR 2544; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-29-4 Auxiliary system

Authority: IC 25-26-13-4
Affected: IC 25-26-13-25

Sec. 4. In the event that a pharmacy which employs such an electronic data processing system experiences system down time, the pharmacy must have an auxiliary procedure which will be used for documentation of refills of prescription orders. This auxiliary procedure must insure that refills are authorized by the original prescription order, that the maximum number of refills has not been exceeded, and that all of the appropriate data is retained for on-line service. However, nothing in this section shall preclude a pharmacist from using his professional judgment to benefit the health of the patient. (Indiana Board of Pharmacy; 856 IAC 1-29-4; filed Aug 16, 1984, 3:55 pm: 7 IR 2544; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-29-5 Safeguards

Authority: IC 25-26-13-4

856 IAC 1-29-6 Data entry; supervision

Authority: IC 25-26-13-4
Affected: IC 25-26-13-25

Sec. 6. When electronic data processing equipment is utilized in any pharmacy, input of drug information shall be performed by a pharmacist or under the immediate and personal supervision of a pharmacist. The pharmacist must certify the accuracy of the information entered and verify the prescription or drug order. (Indiana Board of Pharmacy; 856 IAC 1-29-6; filed Aug 16, 1984, 3:55 p.m.: 7 IR 2545; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-29-7 Existing systems; compliance date (Repealed)

Sec. 7. (Repealed by Indiana Board of Pharmacy; filed Dec 2, 2001, 12:35 p.m.: 25 IR 1340)

856 IAC 1-29-8 Transfer of prescriptions between pharmacies (Repealed)

Sec. 8. (Repealed by Indiana Board of Pharmacy; filed Jun 8, 1992, 5:00 p.m.: 15 IR 2249)

856 IAC 1-29-9 Applicability of rule

Authority: IC 25-26-13-4
Affected: IC 25-26-13-25

Sec. 9. This rule applies to pharmacies with category I and category III permits. (Indiana Board of Pharmacy; 856 IAC 1-29-9; filed Aug 16, 1984, 3:55 p.m.: 7 IR 2545; filed Mar 8, 1989, 10:00 a.m.: 12 IR 1634; filed Jun 8, 1992, 5:00 p.m.: 15 IR 2248; filed Sep 21, 1992, 9:00 a.m.: 16 IR 724; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

Rule 30. Sterile Pharmaceuticals; Preparation and Dispensing

856 IAC 1-30-1 Purpose

Authority: IC 25-26-13-4
Affected: IC 25-26-13-18

Sec. 1. The purpose of this rule is to provide standards for the preparation, labeling, and distribution of sterile pharmaceutical products by licensed pharmacists, pursuant to a drug order or prescription. (Indiana Board of Pharmacy; 856 IAC 1-30-1; filed Jan 28, 1992, 5:00 p.m.: 15 IR 1017; eff Jan 1, 1992 [IC 4-22-2-36 suspends the effectiveness of a rule document for thirty (30) days after filing with the secretary of state. LSA Document #91-6 was filed Jan 28, 1992.]; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-30-2 "Biological safety cabinet" defined

Authority: IC 25-26-13-4
Affected: IC 25-26-13-18
Sec. 2. As used in this rule, "biological safety cabinet" means a containment unit suitable for the preparation of low to moderate risk agents where there is a need for protection of the product, personnel, and environment, according to National Sanitation Foundation (NSF) Standard 49. (Indiana Board of Pharmacy; 856 IAC 1-30-2; filed Jan 28, 1992, 5:00 p.m.: 15 IR 1017, eff Jan 1, 1992 [IC 4-22-2-36 suspends the effectiveness of a rule document for thirty (30) days after filing with the secretary of state. LSA Document #91-6 was filed Jan 28, 1992.]; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; filed Apr 6, 2005, 4:00 p.m.: 28 IR 2385; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-30-3 "Class 100 environment" defined
Authority:  IC 25-26-13-4
Affected:  IC 25-26-13-18

Sec. 3. As used in this rule, "Class 100 environment" means an ISO class 5 atmospheric environment, which contains less than one hundred (100) particles five-tenths (0.5) microns in diameter per cubic foot of air, according to the ISO for clean rooms and associated controlled environments. (Indiana Board of Pharmacy; 856 IAC 1-30-3; filed Jan 28, 1992, 5:00 p.m.: 15 IR 1017, eff Jan 1, 1992 [IC 4-22-2-36 suspends the effectiveness of a rule document for thirty (30) days after filing with the secretary of state. LSA Document #91-6 was filed Jan 28, 1992.]; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; filed Apr 6, 2005, 4:00 p.m.: 28 IR 2385; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-30-4 "Cytotoxic" defined
Authority:  IC 25-26-13-4
Affected:  IC 25-26-13-18

Sec. 4. As used in this rule, "cytotoxic" means a pharmaceutical that has the capability of killing living human cells. (Indiana Board of Pharmacy; 856 IAC 1-30-4; filed Jan 28, 1992, 5:00 p.m.: 15 IR 1017, eff Jan 1, 1992 [IC 4-22-2-36 suspends the effectiveness of a rule document for thirty (30) days after filing with the secretary of state. LSA Document #91-6 was filed Jan 28, 1992.]; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; filed Apr 6, 2005, 4:00 p.m.: 28 IR 2385; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-30-4.1 "Hazardous" defined
Authority:  IC 25-26-13-4
Affected:  IC 25-26-13-18

Sec. 4.1. As used in this rule, "hazardous" means any drug or waste that may:
(1) be:
   (A) cytotoxic;
   (B) genotoxic;
   (C) oncogenic;
   (D) mutagenic;
   (E) teratogenic; or
(2) otherwise pose a potential health hazard. (Indiana Board of Pharmacy; 856 IAC 1-30-4.1; filed Apr 6, 2005, 4:00 p.m.: 28 IR 2385; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-30-4.2 "ISO" defined
Authority:  IC 25-26-13-4
Affected:  IC 25-26-13-18
Sec. 4.2. (a) "ISO" means the International Organization for Standardization. 
(b) That certain document being titled International Organization for Standardization, as published by the International Organization for Standardization 1, rue de Varembé, Case postale 56 CH-1211 Geneva 20, Switzerland, is hereby incorporated by reference as if fully set out in this rule. (Indiana Board of Pharmacy; 856 IAC 1-30-4.2; filed Apr 6, 2005, 4:00 p.m.: 28 IR 2386; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-30-4.3 "NSF" defined 
Authority: IC 25-26-13-4 
Affected: IC 25-26-13-18

Sec. 4.3. (a) "NSF" means the National Sanitation Foundation. 
(b) That certain document being titled The Standard for Performance (copyright 2004), as published by the National Sanitation Foundation, P.O. Box 130140, 789 North Dixboro Road, Ann Arbor, Michigan 48113-0140, is hereby incorporated by reference as if fully set out in this rule. (Indiana Board of Pharmacy; 856 IAC 1-30-4.3; filed Apr 6, 2005, 4:00 p.m.: 28 IR 2386; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-30-4.4 "Parenteral" defined 
Authority: IC 25-26-13-4 
Affected: IC 25-26-13-18

Sec. 4.4. As used in this rule, "parenteral" means a sterile preparation of drugs for injection through one (1) or more layers of the skin. (Indiana Board of Pharmacy; 856 IAC 1-30-4.4; filed Apr 6, 2005, 4:00 p.m.: 28 IR 2386; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-30-4.5 "Positive patient outcome" defined 
Authority: IC 25-26-13-4 
Affected: IC 25-26-13-18

Sec. 4.5. As used in this rule, "positive patient outcome" means the:
(1) cure or prevention of disease; 
(2) elimination or reduction of symptoms; or 
(3) arresting or slowing of disease process; 
so as to improve the patient's quality of life. (Indiana Board of Pharmacy; 856 IAC 1-30-4.5; filed Apr 6, 2005, 4:00 p.m.: 28 IR 2386; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-30-4.6 "Product quality and characteristics" defined 
Authority: IC 25-26-13-4 
Affected: IC 25-26-13-18

Sec. 4.6. As used in this rule, "product quality and characteristics" means the following:
(1) Sterility. 
(2) Potency associated with environmental quality. 
(3) Preparation activities. 
(4) Checks and tests. 
(Indiana Board of Pharmacy; 856 IAC 1-30-4.6; filed Apr 6, 2005, 4:00 p.m.: 28 IR 2386; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18,
856 IAC 1-30-5 "Qualified pharmacist" defined
Authority: IC 25-26-13-4
Affected: IC 25-26-13-18

Sec. 5. As used in this rule, "qualifying pharmacist" means a licensed pharmacist, identified in the policy and procedure manual, required by section 7 of this rule, as responsible for the preparation of the sterile pharmaceuticals, in compliance with the policy and procedure manual and the applicable laws governing the practice of pharmacy in Indiana. (Indiana Board of Pharmacy; 856 IAC 1-30-5; filed Jan 28, 1992, 5:00 p.m.: 15 IR 1017, eff Jan 1, 1992 [IC 4-22-2-36 suspends the effectiveness of a rule document for thirty (30) days after filing with the secretary of state. LSA Document #91-6 was filed Jan 28, 1992.]; readopted filed Dec 2, 2001, 12:35 p.m.: 25 IR 1337; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-30-6 "Sterile pharmaceutical" defined
Authority: IC 25-26-13-4
Affected: IC 25-26-13-18

Sec. 6. As used in this rule, "sterile pharmaceutical" means any dosage form of a drug, including, but not limited to, parenteral, injectable, and ophthalmic dosage forms, which dose form is free from living microbes and free from chemical or physical contamination. (Indiana Board of Pharmacy; 856 IAC 1-30-6; filed Jan 28, 1992, 5:00 p.m.: 15 IR 1017, eff Jan 1, 1992 [IC 4-22-2-36 suspends the effectiveness of a rule document for thirty (30) days after filing with the secretary of state. LSA Document #91-6 was filed Jan 28, 1992.]; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; filed Apr 6, 2005, 4:00 p.m.: 28 IR 2386; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-30-7 Policy and procedure manual
Authority: IC 25-26-13-4
Affected: IC 25-26-13-18

Sec. 7. Each pharmacy preparing and dispensing, or holding itself out to prepare or dispense, sterile pharmaceuticals shall maintain a policy and procedure manual relating to the compounding, dispensing, delivery, administration, storage, and use of sterile pharmaceutical products, pursuant to prescriptions or drug orders, or both, as part of the pharmacy policy and procedure manual or as a separate policy and procedure manual. This manual shall be available at the pharmacy for inspection by the board or its designated inspector. The manual shall be reviewed annually by the pharmacist-in-charge or the qualifying pharmacist and revised if needed. The manual shall include the name of the pharmacist-in-charge of the preparation of sterile pharmaceuticals and policies and procedures for the following:

(1) Clinical services provided.
(2) The handling, storage, disposal, and cleanup of accidental spills of hazardous drugs, if they are prepared.
(3) Disposal of unused supplies and drugs.
(4) Drug destruction and returns.
(5) Drug dispensing.
(6) Drug labeling and relabeling.
(7) Drug storage.
(8) Duties and qualifications for professional and nonprofessional staff.
(9) Equipment.
(10) Handling of infectious wastes, if drug products or administration devices are returned to the pharmacy after administration in the case of home administration.
(11) Infusion devices and drug delivery systems, if utilized.
(12) Investigational drugs, if dispensed.
(13) Quality assurance procedures to include the following:
   (A) Recall procedures.
   (B) Storage and expiration dating.
   (C) Educational procedures for professional staff, nonprofessional staff, and the patient, if needed, in the case of home administration.
   (D) Sterile procedures to include monitoring the temperature of the refrigerator, routine maintenance, and report of hood certification.
   (E) Sterility testing or monitoring, if employed, in the case of routine bulk compounding from nonsterile chemicals.

(14) Reference manuals.

(15) Sterile product preparation procedures.

856 IAC 1-30-8 Physical requirements

Authority: IC 25-26-13-4
Affected: IC 25-26-13-18

Sec. 8. (a) A licensed pharmacy preparing sterile pharmaceuticals shall have a designated area for preparing compounded, sterile pharmaceuticals. The designated area shall be restricted to only those personnel authorized for the preparation of sterile pharmaceuticals. This area may be in a separate room or in a portion of a larger room. The area cannot be a warehouse or stockroom setting and must be free of dust and dirt.

(b) The designated preparation area shall be used only for the preparation of sterile pharmaceutical products and related functions.

(c) The licensed pharmacy preparing sterile pharmaceutical products shall have the following equipment:

1. An environmental control device capable of maintaining at least an ISO Class 5 (Class 100) environment in the work space where critical objects are exposed and critical activities are performed. This device must be capable of maintaining ISO Class 5 (Class 100) conditions during normal activity. Examples of appropriate devices include the following:
   (A) Laminar airflow hood.
   (B) Zonal laminar flow of high efficiency particulate air (HEPA) filtered air.
   (C) Barrier isolators.

2. A sink with hot and cold running water that is convenient to the compounding area but outside the buffer area for the purpose of hand scrubs before compounding.

3. Disposal containers for used needles, syringes, gowns, gloves, etc., and, if applicable, for hazardous waste from the preparation of chemotherapy agents and infectious wastes from patients.

4. Environmental controls including biohazard cabinetry when hazardous drug products are prepared.

5. A refrigerator with a thermometer.

6. Infusion devices, if appropriate.

7. Documentation to demonstrate adequate cleaning and sanitizing of the environment along with records of all necessary air sampling for particulates and microorganisms.

8. Environmental control to maintain an ISO Class 8 (Class 100,000) conditions in the buffer area.

(d) The pharmacy shall maintain supplies adequate to maintain an environment suitable for the aseptic preparation of sterile products. All expired, recalled, or adulterated and misbranded drug substances must be removed from the restricted area. The licensed pharmacy preparing sterile pharmaceuticals shall include the following supplies:

1. Disposable needles, syringes, and other supplies needed for aseptic admixture.
2. Disinfectant cleaning tools and solutions.
3. A hand washing agent with antibacterial action.
4. Disposable towels or wipes.
(5) Filters and filtration equipment, if utilized.
(6) A hazardous drug spill kit shall be available in the facility if hazardous drugs are prepared.
(7) Disposable gowns and gloves.
(e) No one may have access to the pharmacy in the absence of the pharmacist, except as stated in 856 IAC 1-28.1-8.
(f) The pharmacy shall have sufficient current reference materials related to sterile products to meet the needs of pharmacy.

A pharmacy preparing or proposing to prepare sterile pharmaceuticals shall have in its reference library:
(1) the Handbook on Injectable Drugs, published by the American Society of Hospital Pharmacists (ASHP), 4630 Montgomery Avenue, Bethesda, Maryland 20814;
(2) the King's Guide to Parenteral Admixtures, published by Pacemarq Inc., 11701 Borman Drive, St. Louis, Missouri 63146;
or
(3) another board-approved printed or electronic database sufficient for determining mixing and administration guidelines and drug incompatibilities such as would be contained in the references listed in subdivision (1) or (2).

g) If the pharmacy is handling or preparing hazardous drugs, the pharmacy shall have a current copy of Occupational Safety and Health Administration requirements for handling hazardous drugs as published by the Occupational Safety and Health Administration, Office of Occupational Medicine, Directorate of Technical Support, Occupational Safety and Health Administration, U.S. Department of Labor. (Indiana Board of Pharmacy; 856 IAC 1-30-8; filed Jan 28, 1992, 5:00 p.m.: 15 IR 1018, eff Jan 1, 1992 [IC 4-22-2-36 suspends the effectiveness of a rule document for thirty (30) days after filing with the secretary of state. LSA Document #91-6 was filed Jan 28, 1992]; errata filed Mar 17, 1992, 10:20 a.m.: 15 IR 1394; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; filed Apr 6, 2005, 4:00 p.m.: 28 IR 2387; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-30-9 Personnel
Authority: IC 25-26-13-4
Affected: IC 25-26-13-18

Sec. 9. (a) Each pharmacist, pharmacist intern, pharmacist extern, and pharmacy technician engaged in preparing sterile pharmaceuticals must be trained in the specialized functions of preparing and dispensing compounded, sterile pharmaceuticals, including the principles of aseptic technique and quality assurance. Documentation of such training or experience shall be made available for inspection by the board or its representatives.

(b) The qualifying pharmacist shall be responsible for the following:
(1) Purchasing, storage, compounding, repackaging, dispensing, and distribution of all sterile pharmaceuticals.
(2) Development and continuing review of all:
   (A) policies and procedures;
   (B) training manuals; and
   (C) quality assurance programs.

(c) The qualifying pharmacist shall:
(1) assure the environmental control of all products shipped, as controllable by the pharmacist to the extent such aspect of shipping is controllable by the pharmacist; and
(2) be responsible for adherence to all current USP Standards related to sterile compounding, personnel cleansing and gowning;

or
(3) reject or cause to be rejected any such shipment or drugs as prepared in violation of applicable USP Standards. (Indiana Board of Pharmacy: 856 IAC 1-30-9; filed Jan 28, 1992, 5:00 p.m.: 15 IR 1019, eff Jan 1, 1992 [IC 4-22-2-36 suspends the effectiveness of a rule document for thirty (30) days after filing with the secretary of state. LSA Document #91-6 was filed Jan 28, 1992]; readopted filed Dec 2, 2001, 12:35 p.m.: 25 IR 1337; filed Apr 6, 2005, 4:00 p.m.: 28 IR 2388; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)
856 IAC 1-30-10  Support personnel

Sec. 10. (a) The pharmacist may be assisted by support personnel in compliance with IC 25-26-13-18(a)(4). Such personnel shall have specialized training in the preparation of sterile pharmaceuticals and shall work under the supervision of a licensed pharmacist. The training provided to these personnel shall be described in writing. The duties and responsibilities of supportive personnel must be consistent with their training and experience.

(b) This section is not to preclude other licensed health care professionals, as allowed by law, may also prepare sterile pharmaceuticals when there is an immediate need, or when the preparation in a pharmacy is not practical.

856 IAC 1-30-11  Staffing

Sec. 11. A pharmacist shall be accessible at all times to respond to patients' and other health professionals' questions and needs.

856 IAC 1-30-12  Profile or medication record system

Sec. 12. A pharmacy-generated profile or medication record system for sterile pharmaceuticals administered to patients, except for those inpatients in an institutional facility, as defined in 856 IAC 1-28-1(a), holding a Type II pharmacy permit, shall be maintained separately from the prescription file. The patient profile or medication record system shall contain at a minimum the following:

1. Patient's name, date of birth or age, weight, and sex.
2. Sterile pharmaceutical products dispensed.
3. Drug content and quantity.
4. Directions for the patient, if administered outside the facility.
5. Identification of the dispensing pharmacist and other authorized personnel responsible for preparing the sterile pharmaceutical.
6. Other drug therapy information, if applicable.
7. Known or suspected drug sensitivities and allergies of the patient to drugs and foods, if applicable.
8. Primary diagnosis and chronic conditions if the sterile pharmaceutical is administered outside the facility.
856 IAC 1-30-13 Labeling
Authority:  IC 25-26-13-4
Affected:  IC 25-26-13-18

Sec. 13. (a) Each sterile pharmaceutical product dispensed to a patient shall be labeled with the following:
   (1) Date of preparation by the pharmacy.
   (2) Patient name and bed number, if an institutionalized patient.
   (3) Name of each drug in the preparation, strength, and amount.
   (4) Expiration date of the preparation, including time, if applicable.
   (5) Identity of the pharmacist compounding and dispensing the sterile pharmaceutical, and identity of other authorized personnel preparing the product, if applicable.
   (6) Other information required by the dispensing pharmacy regarding storage requirements or special warnings.
(b) In addition, if the patient residing at home or outside the facility where the sterile pharmaceutical is prepared, the following labeling requirements apply:
   (1) Identifying prescription number.
   (2) Prescriber's full name.
   (3) Name, address, and telephone number of the licensed pharmacy.
   (4) Directions for use shall be provided, either on the label or by other written instructions, including infusion rate and date and time of administration.

856 IAC 1-30-14 Records and reports
Authority:  IC 25-26-13-4

Sec. 14. (a) The qualifying pharmacist shall be responsible for such records and reports as required to ensure the patient's health, safety, and welfare. Such records shall be readily available and maintained for two (2) years from the date of issuance of the prescription or drug order and be subject to inspection by the Indiana board of pharmacy or its designated inspector. These records shall include the following:
   (1) Patient profile or medication record system.
   (2) Policy and procedure manual.
   (3) Training manuals.
   (4) Policies and procedures for disposal of hazardous waste, when applicable.
(b) Information regarding individual patients shall be maintained in a manner to assure confidentiality of the patient's record. Release of this information shall be in accordance with IC 25-26-13-15.
   (c) If appropriate, the qualifying pharmacist must document the patient's training and competency in managing this type of therapy provided by the pharmacist to the patient in the home environment. A pharmacist must be involved in the patient training process in any area that related to drug:
   (1) compounding;
   (2) labeling;
   (3) administration;
   (4) storage;
   (5) stability;
   (6) compatibility; or
   (7) disposal.
The pharmacist shall be responsible for seeing that the patient's competency in the areas in subdivisions (1) through (7) is reassessed
Disposal of infectious waste

Authority: IC 25-26-13-4
Affected: IC 25-26-13-18

Sec. 15. The qualifying pharmacist is responsible for assuring that there is a system for the disposal of infectious waste returned from outside the facility in a manner consistent with the protection of the public's health and safety and in compliance with applicable state and federal law. (Indiana Board of Pharmacy; 856 IAC 1-30-15; filed Jan 28, 1992, 5:00 p.m.: 15 IR 1020, eff Jan 1, 1992 [IC 4-22-2-36 suspends the effectiveness of a rule document for thirty (30) days after filing with the secretary of state. LSA Document #91-6 was filed Jan 28, 1992.]; readopted filed Dec 2, 2001, 12:35 p.m.: 25 IR 1338; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

Emergency kit

Authority: IC 25-26-13-4
Affected: IC 25-26-13-18

Sec. 16. When sterile pharmaceuticals are provided to home care patients, the dispensing pharmacy may supply the nurse with emergency drugs, if the treating physician has authorized the use of such drugs by a protocol, for use in an emergency situation, e.g., anaphylactic shock. (Indiana Board of Pharmacy; 856 IAC 1-30-16; filed Jan 28, 1992, 5:00 p.m.: 15 IR 1020, eff Jan 1, 1992 [IC 4-22-2-36 suspends the effectiveness of a rule document for thirty (30) days after filing with the secretary of state. LSA Document #91-6 was filed Jan 28, 1992.]; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

Hazardous drugs

Authority: IC 25-26-13-4
Affected: IC 25-26-13-18

Sec. 17. In addition to the minimum requirements for a pharmacy established by rules of the board, the following requirements are necessary to ensure the protection of the personnel involved in those licensed pharmacies that prepare hazardous drugs:

1. All hazardous drugs shall be compounded in a Class II, biological safety cabinet. If this cabinet is not dedicated solely to the compounding of hazardous drugs, policies and procedures must be in place for the cleaning and decontaminating this biological safety cabinet.
2. Protective apparel shall be worn by personnel compounding hazardous drugs. This shall include disposable gloves and gowns with tight cuffs.
3. Appropriate safety and containment techniques for compounding hazardous drugs shall be used in conjunction with the aseptic techniques required for preparing sterile products.
4. Procedures for disposal of hazardous waste shall be specified within the policy and procedure manual as required by section 7 of this rule and comply with all applicable local, state, and federal requirements.
5. Written procedures for handling both major and minor spills of hazardous agents must be developed and included in the policy and procedure manual.
6. Prepared doses of hazardous drugs shall be dispensed and labeled with proper precautions inside and outside and shipped in a manner designed to minimize the risk of accidental rupture of the primary container.
856 IAC 1-30-18 Quality assurance

Authority: IC 25-26-13-4
Affected: IC 25-26-13-18

Sec. 18. (a) The designated qualifying pharmacist shall conduct a documented, ongoing quality assurance program that monitors personnel performance, equipment, and facilities. Samples of finished products shall be examined, or other continuous monitoring methods shall be used to assure that the pharmacy is capable of consistently preparing sterile pharmaceuticals meeting specifications in accordance with good compounding practices and the current USP/NF Chapter on sterile preparation. Quality assurance procedures shall include the following:

1. Recall procedures for compounded sterile pharmaceuticals.
2. Storage and dating for compounded sterile pharmaceuticals.
3. Sterile procedures, including the following:
   A. Monitoring the temperature of the refrigerator.
   B. Routine maintenance.
   C. Report of laminar flow hood certification.
4. Written documentation of periodic hood cleaning.

(b) All biological safety cabinets and Class 100 environments shall be certified by an independent contractor or facility specialist as meeting Federal Standard 209B or National Sanitation Foundation Standard 49, as referenced in section 2 of this rule, for operational efficiency. Such certification shall be performed every six (6) months. Records documenting certification, which, at a minimum, includes laminar air flow velocity and particle count, shall be maintained for a period of not less than two (2) years.

(c) Prefilters for the clean air source shall be replaced or cleaned as applicable on a regular basis and the replacement or cleaning date documented.

(d) A vertical flow Class II biological safety cabinet may be used to compound any sterile pharmaceutical product; however, the cabinet must be thoroughly cleaned between each use for hazardous and nonhazardous drug compounding.

(e) If manufacturing of parenteral solutions is performed utilizing nonsterile chemicals, extensive end product testing, as referenced in Remington's Pharmaceutical Sciences, published by Mack Publishing Company, Easton, Pennsylvania 18042, or other Federal Drug Administration approved testing methods, must be documented prior to the release of the product from quarantine. This process must include appropriate tests for particulate matter, microbial contamination, and testing for pyrogens. This does not preclude the extemporaneous compounding of certain sterile pharmaceuticals.

(f) There shall be:
1. written justification of the chosen expiration dates for compounded parenteral products documented in the policy and procedure manual; and
2. documentation of quality assurance audits at planned intervals, including infection control and sterile technique audits.

Rule 31. Facsimile Machines

856 IAC 1-31-1 "Facsimile machine" defined

Authority: IC 25-26-13-4
Affected: IC 25-26-13-2
Sec. 1. As used in this rule, "facsimile machine" means a machine that electronically transmits exact images through connection with a telecommunications network. (Indiana Board of Pharmacy: 856 IAC 1-31-1; filed Mar 31, 1992; 5:00 p.m.: 15 IR 1390; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA4; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-31-2 Use of a facsimile machine to electronically transmit a prescription or drug order

Authority: IC 25-26-13-4
Affectsed: IC 25-26-13-15

Sec. 2. Prescription or drug orders for legend drugs, including schedules II through V substances, may be transmitted by facsimile machine from an authorized prescribing practitioner or an authorized employee or agent of the individual practitioner to a pharmacy under the following restrictions:

1. A prescription or drug order for a schedule II controlled substance may be transmitted to a pharmacy via facsimile equipment, provided the original written, signed prescription or drug order is presented to the pharmacist for review prior to the actual dispensing of the controlled substance, except as noted in subdivision (2) or (3).

2. A prescription or drug order prepared in accordance with 856 IAC 2-6-4 written for a schedule II narcotic substance to be compounded for the direct administration to a patient in a private residence, long-term care facility, or hospice setting by means of:
   (A) parenteral;
   (B) intravenous;
   (C) intramuscular;
   (D) subcutaneous; or
   (E) intraspinal;
   infusion may be transmitted by facsimile.

3. A prescription or drug order prepared in accordance with 856 IAC 2-6-4 written for a schedule II substance for a resident of a long-term care facility licensed under 410 IAC 16.2-3.1 may be transmitted to the dispensing pharmacy by facsimile.

4. A prescription or drug order prepared in accordance with 856 IAC 2-6-4 written for a schedule II narcotic substance for a patient enrolled in a hospice program, inpatient or outpatient, certified by Medicare under Title XVIII or licensed by Indiana may be transmitted to the dispensing pharmacy by facsimile. The practitioner or the practitioner's agent will note on the prescription or drug order that the patient is a hospice patient.

5. The receiving facsimile machine must be located in the nonpublic area of the licensed pharmacy to protect patient/pharmacist/authorizing prescribing practitioner confidentiality and security as required by IC 25-26-13-15.

6. Using facsimile equipment to circumvent documentation, authenticity, verification, or other standards of the profession of pharmacy as defined by IC 25-26-13 or this title will be considered professional incompetence under IC 25-1-9.

856 IAC 1-31-3 Facsimile prescription or drug order maintenance

Authority: IC 25-26-13-4
Affectsed: IC 25-26-13-25

Sec. 3. The facsimile serves as the original written prescription or drug order, and it shall be maintained in accordance with IC 25-26-13-25. (Indiana Board of Pharmacy: 856 IAC 1-31-3; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)
Rule 32. Transfer of Prescriptions Between Pharmacies

856 IAC 1-32-1 Applicability of rule
Authority: IC 25-26-13-4
Affected: IC 25-26-13-25

Sec. 1. This rule governs the transfer of prescription information, either originally filled or previously refilled, by one (1) pharmacy to another pharmacy for refills. (Indiana Board of Pharmacy; 856 IAC 1-32-1; filed Jun 8, 1992, 5:00 p.m.: 15 IR 2248; readopted filed Dec 2, 2001, 12:35 p.m.: 25 IR 1339; readopted filed Sep 26, 2008, 10:55 a.m.: 20081015-IR-856080346RFA; readopted filed Dec 1, 2014, 8:33 a.m.: 20141231-IR-856140392RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-32-2 Noncontrolled and controlled substance prescription transfers
Authority: IC 25-26-13-4
Affected: IC 25-26-13-25

Sec. 2. (a) Prescription information for legend drugs that are not controlled substances may be transferred at any time during the lifetime of the prescription up to one (1) year after the date originally issued by the prescriber or when the original number of authorized refills expires, whichever comes first.
(b) Except as limited by the requirement of subsection (a), prescriptions for legend drugs that are not controlled substances may be transferred any number of times.
(c) If any authorized refills remain, prescriptions for schedule III, schedule IV, and schedule V controlled substances may be transferred only once within six (6) months from the date the prescription was issued. However, pharmacies electronically sharing a real-time, online database may transfer up to the maximum refills permitted by law and the prescriber's authorization.
(d) Prescriptions for schedule II controlled substances may not be transferred. (Indiana Board of Pharmacy; 856 IAC 1-32-2; filed Jun 8, 1992, 5:00 p.m.: 15 IR 2248; filed May 26, 2000, 8:52 a.m.: 23 IR 2503; readopted filed Dec 2, 2001, 12:35 p.m.: 25 IR 1339; readopted filed Sep 26, 2008, 10:55 a.m.: 20081015-IR-856080346RFA; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-32-3 Patient's right to transfer prescriptions
Authority: IC 25-26-13-4
Affected: IC 25-26-13-16; IC 25-26-13-25

Sec. 3. A pharmacist may not legally refuse to transfer a patient's prescription or prescription information except when to do so would be against the professional judgment of the pharmacist in the manner provided for under IC 25-26-13-16. (Indiana Board of Pharmacy; 856 IAC 1-32-3; filed Jun 8, 1992, 5:00 p.m.: 15 IR 2248; errata filed Jul 10, 1992, 9:00 a.m.: 15 IR 2465; readopted filed Dec 2, 2001, 12:35 p.m.: 25 IR 1339; readopted filed Sep 26, 2008, 10:55 a.m.: 20081015-IR-856080346RFA; readopted filed Dec 1, 2014, 8:33 a.m.: 20141231-IR-856140392RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-32-4 Pharmacists' responsibilities
Authority: IC 25-26-13-4
Affected: IC 25-26-13-25

Sec. 4. Transfer of prescription information must be communicated between licensed pharmacists or licensed pharmacist interns in accordance with this title and all applicable U.S. Drug Enforcement Administration regulations and must meet the following requirements:
1. The pharmacist or pharmacist intern transferring the prescription shall do the following:
   (A) Indicate that the prescription is no longer active and has been transferred.
   (B) Record the name, address, and U.S. Drug Enforcement Administration registration number of the pharmacy to which it was transferred and the name of the pharmacist receiving the prescription.
(C) Record the date of the transfer and the name of the pharmacist transferring the information.

(2) The pharmacist or pharmacist intern receiving the transferred prescription shall record the following:
   (A) All information required to be on a prescription and include the following:
      (i) Date of issuance of original prescription.
      (ii) Original number of refills authorized on original prescriptions.
      (iii) Date of original dispensing.
      (iv) Number of valid refills remaining and date of last refill and, in the event the transfer is for the second or
           subsequent transfer of a substance that is a schedule III, schedule IV, or schedule V controlled substance, the date
           and location of the previous refill.
      (v) Pharmacy's name, address, U.S. Drug Enforcement Administration registration number, and original
           prescription number from which the prescription information was transferred.
      (vi) Name of the pharmacist, and pharmacist intern if applicable, transferring and receiving the transferred
           prescription.
   (B) Both the original and transferred prescription must be maintained as required under IC 25-26-13-25.

856 IAC 1-32-5 Electronic transfers

Sec. 5. (a) Two (2) or more pharmacies may establish and use a common electronic file to maintain required information related
         to the practice of the profession of pharmacy.

         (b) Pharmacies using such a common electronic file are not required to transfer prescriptions or information for dispensing
             purposes between or among pharmacies participating in the same common prescription file as described in section 4 of this rule
             provided the following:
             (1) The pharmacies are under common ownership or a contractual agreement.
             (2) Any such common file must contain complete and adequate records of such prescription or prescriptions and refill or refills
                 dispensed according to IC 25-26-13-25.
             (3) All pharmacies and pharmacists involved in the transactions pursuant to the practice of the profession of pharmacy are
                 properly licensed, permitted, or registered within the United States.
             (4) A policy and procedures manual that governs all participating pharmacies and pharmacists:
                 (A) is available to the board upon request; and
                 (B) includes the procedure for maintaining appropriate records for regulatory oversight for tracking a prescription during
                     each stage of the practice of the profession of pharmacy.
             (5) The pharmacists involved in the practice of the profession of pharmacy are identified. A pharmacist shall be accountable
                 for the specific tasks performed.

Rule 33. Counseling

856 IAC 1-33-1 Definitions

Sec. 1. The following definitions apply throughout this rule:
(1) "Counseling" means appropriate communication, by a pharmacist, to a patient, as defined in subdivision (3), of information
for the purpose of improving therapeutic outcomes by maximizing the proper use of drugs and devices dispensed pursuant to prescriptions.

(2) "Offer" means a statement that is verbal or, only if necessary for an individual patient, nonverbal, for example, printed or written, that clearly informs the patient that a pharmacist is available, at the time the offer is made, to counsel the patient, including, but not limited to, giving information to or answering questions, or both, from the patient.

(3) "Patient" means the following:
   (A) The individual for whom a prescription was issued.
   (B) The caregiver of the individual for whom a prescription was issued.
   (C) The agent of the individual for whom a prescription was issued.

Indiana Administrative Code Page 43

856 IAC 1-33-1.5 Offer requirements

Authority: IC 25-26-13-4
Affected: IC 25-26-13-10

Sec. 1.5. (a) The following can satisfy an offer:
(1) A pharmacist counseling the patient.
(2) A pharmacist intern/extern registered under IC 25-26-13-10 if:
   (A) permitted by the pharmacist; and
   (B) the counseling by the pharmacist intern/extern is followed by a bona fide offer for the pharmacist to counsel the patient and if the patient or patient's representative desires such counseling.
(3) A written notice containing the pharmacy's phone number and a bona fide offer when:
   (A) a patient is not present and has not authorized the giving of information to another; or
   (B) the drug or device is delivered by the United States Postal Service, parcel delivery, or hand delivery.
(4) Any personnel in the prescription department, as defined in 856 IAC 1-13-3(b)(3), making an offer to counsel, as defined in section 1(2) of this rule.

(b) The following cannot satisfy an offer:
(1) Making an offer for the patient to ask questions.
(2) Any other method that serves to shift the responsibility from the pharmacists to the patient for initiating the counseling or for selecting the informational content of the counseling.
(3) Relaying information through an intermediary, unless needed for translations, hearing impaired, or other situation beyond the control of the pharmacist.
(4) Using signs or other types of written notices or written information given to the patient with each drug dispensed.

856 IAC 1-33-2 Patient counseling requirements

Authority: IC 25-26-13-4
Affected: IC 25-26-13-16

Sec. 2. (a) Upon the receipt of a prescription or upon the subsequent refilling of a prescription, and following a review of the patient's prescription medication profile, the pharmacist shall be responsible for the initiation of an offer, as set forth in section 1.5(a) of this rule, to counsel the patient on matters that, in the pharmacist's professional judgment, are significant to optimizing drug therapy. Depending upon the situation, these matters may include, but are not necessarily limited to, the following:
(1) The name and description of the medicine.
(2) The route, dosage form, dosage, route of administration, and duration of drug therapy.
(3) Special directions and precautions.
(4) Common adverse effects or interactions and therapeutic contraindications that may be encountered, including their
avoidance and the action required if they occur.
(5) Techniques for self-monitoring drug therapy.
(6) Proper storage.
(7) Prescription refill information.
(8) Action to be taken in the event of a missed dose.

(b) Counseling shall be in person, whenever practicable, or through access to a telephone service that is toll-free for long
distance calls and be held with the patient, the patient's caregiver, or the patient's representative.

c) Alternative forms of patient information may be used to supplement verbal counseling when appropriate. Examples include
written information leaflets, pictogram labels, and video programs. Nothing in this subsection shall be construed to mean that
supplements may be a substitute for verbal counseling when verbal counseling is practicable.

d) Nothing in this rule shall be construed as requiring a pharmacist to provide counseling when a patient knowingly declines
(waives) the offer to counsel.

e) Requesting or accepting, or both, a waiver for counseling for all prescriptions both present and future is not permitted. An
offer must be made with each prescription-dispensing visit.

(f) The patient's declining of counseling must be documented in either written or electronic format. The required documentation
may be on the same form as or with another pharmacy-related authorization, only if it is clear to the patient that the documentation
form also contains the patient's intent to decline (waive) counseling. The documentation subject to this section shall be retained in
the pharmacy licensed area or in a secure area under the pharmacy's control, which is readily available for inspection, for a period
of not less than two (2) years. (Indiana Board of Pharmacy; 856 IAC 1-33-2; filed Dec 1, 1992, 5:00 p.m.: 16 IR 1176; readopted

856 IAC 1-33-3 Patient profile requirements
Authority: IC 25-26-13-4
Affected: IC 25-26-13-25

Sec. 3. The pharmacist shall assure that prescription medication profiles are maintained for all patients receiving
pharmaceutical care at that pharmacy. Within limits of reasonably available information, the pharmacy medication profile shall
include the following:
(1) Name, address, telephone number, age or date of birth, and gender.
(2) Known drug allergies and adverse reactions.
(3) A list of current medications and relevant devices, either of which may relate to the patient's drug therapy.
(4) Known disease states.
(5) Any other information that, in the pharmacist's professional judgment, the pharmacist deems appropriate.
(6) Pharmacist's comments relevant to the individual's drug therapy.
(Indiana Board of Pharmacy; 856 IAC 1-33-3; filed Dec 1, 1992, 5:00 p.m.: 16 IR 1176; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 17, 2010, 9:52 a.m.: 20101215-IR-856100407RFA; readopted filed Nov 22, 2016, 12:27 p.m.: 20161221-IR-856160320RFA)

856 IAC 1-33-4 Institutional patient exception
Authority: IC 25-26-13-4
Affected: IC 25-26-13-4

Sec. 4. The requirements for patient counseling, as described in this rule, shall not apply to patients residing in institutional
facilities in Indiana as defined under 856 IAC 1-28.1-1(6). (Indiana Board of Pharmacy; 856 IAC 1-33-4; filed Dec 1, 1992, 5:00
p.m.: 16 IR 1177; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; readopted filed Jun 7, 2004, 4:45 p.m.: 27 IR 3074; readopted filed
Nov 17, 2010, 9:52 a.m.: 20101215-IR-856100407RFA; readopted filed Nov 22, 2016, 12:27 p.m.: 20161221-IR-856160320RFA)
856 IAC 1-33-5 Patient counseling violations

Authority: IC 25-26-13-4
Affected: IC 25-1-9

Sec. 5. Violation of this rule shall be grounds for discipline by the board under either IC 25-1-9 or 856 IAC 1-20. (Indiana Board of Pharmacy; 856 IAC 1-33-5; filed Jun 7, 2004, 4:45 p.m.: 27 IR 3074; readopted filed Nov 17, 2010, 9:52 a.m.: 20101215-IR-856100407RFA; readopted filed Nov 22, 2016, 12:27 p.m.: 20161221-IR-856160320RFA)

Rule 34. Security Features for Prescriptions

856 IAC 1-34-1 Applicability

Authority: IC 25-26-24-22
Affected: IC 16-42-19-5; IC 25-26-24-17

Sec. 1. This rule establishes minimum standards for security features for prescriptions issued by practitioners as described in IC 16-42-19-5. Practitioners licensed in Indiana must comply with this rule in order for their prescriptions to be accepted for filling in licensed Indiana pharmacies. (Indiana Board of Pharmacy; 856 IAC 1-34-1; filed Jul 5, 1995, 9:45 a.m.: 18 IR 2782, eff Jan 1, 1996; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-34-2 Security feature requirements

Authority: IC 25-26-24-22
Affected: IC 16-42-19-5; IC 25-26-24-17

Sec. 2. (a) All controlled substance prescriptions written by licensed Indiana practitioners, as defined by IC 16-42-19-5, must contain the following security features:

(1) A latent, repetitive "void" pattern screened at five percent (5%) in reflex blue must appear across the entire face of the document when the prescription is photocopied.

(2) There shall be a custom artificial watermark printed on the back side of the base paper so that it may only be seen at a forty-five (45) degree angle. The watermark shall consist of the words "Indiana Security Prescription", appearing horizontally in a step-and-repeated format in five (5) lines on the back of the document using 12-point Helvetica bold type style.

(3) An opaque RX symbol must appear in the upper right-hand corner, one-eighth (1/8) of an inch from the top of the pad and five-sixteenths (5/16) of an inch from the right side of the pad. The symbol must:
   (A) be three-fourths (3/4) inch in size; and
   (B) disappear if the prescription copy is lightened.

(4) Six (6) quantity check-off boxes must be printed on the form and the following quantities must appear and the appropriate box be checked off for the prescription to be valid:
   (A) 1–24.
   (B) 25–49.
   (C) 50–74.
   (D) 75–100.
   (E) 101–150.
   (F) 151 and over.

(5) No advertisements may appear on the front or back of the prescription blank.

(6) Logos, defined as a symbol utilized by an individual, professional practice, professional association, or hospital, may appear on the prescription blank. The upper left one (1) inch square of the prescription blank is reserved for the purpose of logos. Only logos, as defined by this subdivision, may appear on the prescription blank.

(7) Only one (1) prescription may be written per prescription blank. The following statement must be printed on the bottom of the pad: "Prescription is void if more than one (1) prescription is written per blank.".
(8) Refill options that can be circled by the prescriber must appear below any logos and above the signature lines on the left side of the prescription blank in the following order:

Refill NR 1 2 3 4 5 Void after _____.

(9) Practitioner name and state issued professional license number must be preprinted, stamped, or manually printed on the prescription.

(10) All prescription blanks printed under this rule shall be four and one-fourth (4 1/4) inches high and five and one-half (5 1/2) inches wide.

(b) Nothing in this rule shall prevent licensed Indiana practitioners from utilizing the following:

(1) Security paper prescriptions for the prescribing of any legend drug.

(2) Electronic prescribing in accordance with this title and applicable U.S. Drug Enforcement Administration rules and regulations.

Sec. 3. The name of any controlled substance, as defined by IC 35-48-2, may not be preprinted on any prescription forms at any time before the prescription is being prepared and executed for presentation to the patient or the patient's agent. That includes, but is not limited to, such activities as typing prescriptions in anticipation of their need, and using a rubber stamp or other similar means which would accomplish the same end. Commercially printed forms containing names of controlled substances are also prohibited.

Sec. 4. Prescriptions utilized by pharmacists to record call-in prescriptions, transferred prescriptions, or facsimile prescriptions do not need to comply with this rule.

Sec. 5. Printers wishing to supply prescription blanks to authorized recipients must obtain a template design from the board to use as a layout guide. Printers must also submit a preprint proof to the board for approval prior to any production of prescription blanks governed by this rule.

Rule 35. Pharmacy Technicians
856 IAC 1-35-1 Purpose and scope

Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 1. (a) The board is responsible for establishing standards for the competent practice of pharmacy.
(b) The use of pharmacy technicians to assist the pharmacist with nondiscretionary functions associated with the practice of pharmacy enables the pharmacist to provide pharmaceutical care to the patient.
(c) Evolved pharmacy practice demands additional time for pharmacists to counsel individual patients regarding the proper use of drugs.
(d) Only pharmacists (licensed under IC 25-26-13-11), pharmacy interns and externs (as defined in IC 25-26-13-2 and registered under IC 25-26-13-10), and pharmacy technicians as described in this section shall be permitted to participate in the activities associated with a drug order or prescription preparation.
(e) A pharmacist shall not permit a pharmacy technician to participate in the activities associated with a drug order or prescription preparation unless the pharmacy technician meets the qualifications of this section.
(f) The pharmacist is responsible for the work performed by the pharmacy technician under the pharmacist's supervision.

856 IAC 1-35-2 "Unlicensed person" defined (Repealed)

Sec. 2. (Repealed by Indiana Board of Pharmacy; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA)

856 IAC 1-35-3 "Pharmaceutical care" defined (Repealed)

Sec. 3. (Repealed by Indiana Board of Pharmacy; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA)

856 IAC 1-35-4 Qualifications

Authority: IC 25-26-13-4
Affected: IC 25-26-13-18

Sec. 4. To be eligible to perform the functions and duties of a pharmacy technician, an individual must possess the following qualifications, which shall be ascertained and documented in a reasonably retrievable manner by the pharmacist that qualifies the pharmacy permit:
(1) The individual has not been convicted of a crime that has a direct bearing on the individual's ability to work with legend drugs or controlled substances.
(2) The individual must be a high school graduate or have successfully completed a General Education Development program or have been judged to be competent by the qualifying pharmacist.
(3) The individual must have successfully completed or be enrolled in and successfully complete within twelve (12) months of being hired as a technician one (1) of the following board-approved programs:
   (A) A comprehensive curricular-based education and training program conducted by a pharmacy or educational organization.
   (B) A technician training program utilized by the employer that includes specific training in the duties required to assist the pharmacist in the technical functions associated with the practice of pharmacy. The contents of the training program shall include, at a minimum, the following:
      (i) Understanding of the duties and responsibilities of the technician and the pharmacist, including the standards of patient confidentiality and ethics governing pharmacy practice.
      (ii) Tasks and technical skills, policies, and procedures related to the technician's position.
      (iii) Working knowledge of pharmaceutical-medical terminology, abbreviations, and symbols commonly used...
(iv) Working knowledge of the general storage, packaging, and labeling requirements of drugs, prescriptions, or drug orders.
(v) Ability to perform the arithmetic calculations required for the usual dosage determinations.
(vi) Working knowledge and understanding of the essential functions related to drug purchasing and inventory control.
(vii) The record keeping functions associated with prescriptions or drug orders.

(4) In lieu of the requirements in subdivision (3), the successful completion of a board-approved certification examination may satisfy the requirements of this section.

(5) A record of the pharmacy technician training and education must be maintained in the pharmacy where the technician is employed and shall include the following:
   (A) The name of the pharmacy technician.
   (B) The starting date of employment as a pharmacy technician.
   (C) The starting date of the technician training program.
   (D) The date of completion of the training program or proof of passing the board-approved examination if subdivision (4) applies.
   (E) A copy of the training manual, if on-the-job training is used by the employer, or certificate of successful completion of another approved program, or other training program completed prior to employment.

856 IAC 1-35-5 Duties that a pharmacy technician may not perform

Authority: IC 25-26-13-4
Affected: IC 25-26-13-18

Sec. 5. A pharmacy technician may perform many technical functions associated with the practice of pharmacy. However, even under the immediate and direct supervision of a pharmacist, the pharmacy technician is prohibited from performing the following functions:

(1) Any duty required by law, regulation, or rule to be performed by a pharmacist.
(2) The provision of advice or consultation with the prescriber or other licensed health care provider regarding the patient or the interpretation and application of information contained in the prescription or drug order, medical record, or patient profile.
(3) The provision of advice or consultation with the patient regarding the interpretation of the prescription or the application of information contained in the patient profile or medical record.
(4) Dispensing of prescription drug information to the patient as required in IC 25-26-13-4.
(5) Receipt of a verbal prescription, other than a refill approval or denial, from a prescriber.
(6) Final check on all aspects of the completed prescription and assumption of the responsibility for the filled prescription, including, but not limited to, accuracy of the:
   (A) drug;
   (B) strength; and
   (C) labeling.

856 IAC 1-35-6 Provision of quality assurance; duties (Repealed)

Sec. 6. (Repealed by Indiana Board of Pharmacy; filed Dec 20, 2002, 12:17 p.m.: 26 IR 1562)
856 IAC 1-35-7 Identification
Authority: IC 25-26-13-4
Affected: IC 25-26-13-18

Sec. 7. (a) The public shall be able to identify a pharmacist from a pharmacy technician while engaged in the provision of pharmaceutical care.

(b) A pharmacy technician shall:
   (1) wear identification clearly stating that the person is a pharmacy technician while on duty; and
   (2) identify himself or herself verbally in any telephonic or electronic communication as a pharmacy technician.

(c) No person, other than a person who has met the qualifications established in section 4 of this rule, will be permitted to wear identification using the words "pharmacy technician" or similar wording that may confuse or deceive another person.

Rule 36. Temporary Variances

856 IAC 1-36-1 Exceptions
Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 1. A person subject to the regulations of the board may request that the board grant a temporary variance from any rule adopted by the board, except rules concerning examinations, experience hours, and requirements for licensure.

856 IAC 1-36-2 Submission of a request for temporary variance
Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 2. A request for a temporary variance must be submitted to the board in writing. Each request must contain the following information:

   (1) The name, address, and license or permit number of the applicant.
   (2) The name of the responsible pharmacist and the specific location at which activities will be conducted under the temporary variance.
   (3) The citation to the specific rule from which the applicant seeks a temporary variance.
   (4) A detailed explanation of the purpose of the temporary variance.
   (5) An assessment of the impact on the public if the variance is granted.
   (6) A statement of the conditions which would cause the applicant to apply for renewal of the temporary variance.
   (7) The beginning, midpoint, and ending dates of the proposed demonstration project.

856 IAC 1-36-3 Positive impact on delivery of pharmaceutical care
Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 3. Temporary variances shall only be granted for demonstration projects which are expected to have a positive impact.

856 IAC 1-36-4 Period of time

Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 4. The board shall grant a temporary variance for a period of no more than six (6) months. Any person who receives a temporary variance shall submit to the board a written report of the effects of the demonstration project at the midpoint and at the conclusion of the temporary variance. (Indiana Board of Pharmacy; 856 IAC 1-36-4; filed Jul 23, 1998, 4:43 p.m.: 21 IR 4535; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-36-5 Renewal

Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 5. A temporary variance may be renewed by the Indiana board of pharmacy (board) for an additional six (6) months. A temporary variance shall not be renewed more than five (5) times. Requests for renewal of a variance shall be submitted in writing to the board not less than thirty (30) days prior to the expiration of the variance and shall contain at least the information required by section 2 of this rule. (Indiana Board of Pharmacy; 856 IAC 1-36-5; filed Jul 23, 1998, 4:43 p.m.: 21 IR 4535; readopted filed Dec 2, 2001, 12:35 p.m.: 25 IR 1340; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-36-6 Revocation

Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 6. The board may revoke any temporary variance for cause, including, but not limited to, a finding that the temporary variance poses or may pose a threat to public health, safety, or welfare. The person requesting the temporary variance has the obligation to report any such potential threat to the board immediately upon the discovery of such potential threat, or as soon as possible after such discovery. (Indiana Board of Pharmacy; 856 IAC 1-36-6; filed Jul 23, 1998, 4:43 p.m.: 21 IR 4535; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-36-7 Public notice

Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 7. The board shall give public notice of requests for temporary variances at not less than two (2) consecutive regular meetings before voting to grant or deny a request for a temporary variance. (Indiana Board of Pharmacy; 856 IAC 1-36-7; filed Jul 23, 1998, 4:43 p.m.: 21 IR 4535; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)
856 IAC 1-36-8 Justification of denial
Authority: IC 25-26-13-4
Affected: IC 25-26-13


856 IAC 1-36-9 Copies of requests
Authority: IC 25-26-13-4
Affected: IC 25-26-13-5

Sec. 9. The executive director shall retain copies of all requests for temporary variances and the board's reasons for granting or denying requests as part of the record of it proceedings maintained under IC 25-26-13-5. (Indiana Board of Pharmacy; 856 IAC 1-36-9; filed Jul 23, 1998, 4:43 p.m.: 21 IR 4535; readopted filed Nov 13, 2001, 3:55 p.m.: 25 IR 1330; readopted filed Oct 4, 2007, 3:33 p.m.: 20071031-IR-856070060RFA; readopted filed Nov 25, 2013, 9:24 a.m.: 20131225-IR-856130308RFA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

Rule 37. Central Fill or Processing, or Both, of Prescriptions and Drug Orders

856 IAC 1-37-1 "Central fill or processing, or both, of prescriptions and drug orders" defined
Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 1. "Central fill or processing, or both, of prescriptions and drug orders" means, to the extent permissible by law, the filling or processing by a pharmacy of a request from another pharmacy, provider, payor, pharmacy benefit manager, or patient to do the following according to IC 25-26-13:
(1) Fill or dispense, or both, a new or refillable prescription or drug order.
(2) Perform processing or professional, or both, functions, including any of the following:
   (A) Drug utilization review.
   (B) Data entry and evaluation.
   (C) Claims adjudication.
   (D) Refill authorizations.
   (E) Therapeutic interventions.
   (F) Counseling.
   (G) Any other cognitive services as defined under 856 IAC 1-41.
   (H) Other functions as determined or approved by the board on an individual basis that do not adversely impact positive patient outcomes or patient safety.

Indiana Administrative Code

856 IAC 1-37-1.1 Central fill or processing, or both, facilities
Authority: IC 25-26-13-4
Affected: IC 25-26

Sec. 1.1. A pharmacy that performs centralized functions may perform:
(1) either processing or filling functions; and
(2) both functions out of the same facility in accordance with this article and the documented policies and procedures manual.
856 IAC 1-37-1.2 Central fill or processing, or both, supervision

Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 1.2. Central fill or processing, or both, activities must occur in a permitted pharmacy environment under the supervision of a qualifying pharmacist as defined in IC 25-26-13. (Indiana Board of Pharmacy; 856 IAC 1-37-1.2; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-37-1.3 Central fill or processing, or both, remote practice

Authority: IC 25-26-13-4
Affected: IC 25-26

Sec. 1.3. Permitted central fill or central processing pharmacies may engage in remote practice and supervision, but only to the extent that the remote practice and supervision relates to the processing functions discussed in this rule or the delivery of cognitive services defined in 856 IAC 1-41, or both. Those facilities that choose to engage in remote practice shall comply with the following:

1. 856 IAC 1-42-4.
2. 856 IAC 1-42-5.
3. 856 IAC 1-42-6.
4. 856 IAC 1-42-7.

Those facilities that utilize remote practice pharmacy are also required to keep an active record of transactions and individuals that perform remote work that is available for inspection or review. (Indiana Board of Pharmacy; 856 IAC 1-37-1.3; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-37-2 Contracting for central fill or processing, or both

Authority: IC 25-26-13-4
Affected: IC 25-26

Sec. 2. A permitted pharmacy may outsource and contract for central fill or processing, or both, functions provided the involved parties have:

1. the same owner or are employed by the same organization; or
2. a written contract outlining the:
   A. services to be provided; and
   B. responsibilities and accountabilities of each party in fulfilling the terms of the contract in compliance with federal and state laws and regulations and the provisions discussed in section 1 of this rule;
and share a common electronic database or have appropriate technology to allow access to sufficient information necessary or required to process, fill, or refill a prescription or drug order or provide cognitive services, or both. (Indiana Board of Pharmacy; 856 IAC 1-37-2; filed Oct 14, 2005, 1:00 p.m.: 29 IR 816; readopted filed Nov 22, 2011, 12:16 p.m.: 20111221-IR-856110370RFA; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-37-2.1 Contracting for central fill or processing, or both, policies and procedures

Authority: IC 25-26-13-4
Affected: IC 25-26

Sec. 2.1. The pharmacy shall maintain as part of its documented policies and procedures a section addressing its contractual relationship regarding any outsourced or contractually provided services that are performed by another entity. (Indiana Board of
856 IAC 1-37-3 Policy and procedures manual

Authority: IC 25-26-13-4
Affected: IC 25-26

Sec. 3. The parties performing or contracting for central fill or processing, or both, services shall maintain a policy and procedures manual and documentation that implementation is occurring in a manner that shall be made available to the board for review, upon request, and that includes, but it is not limited to, the following:

1. A description of how the parties will comply with federal and state laws and regulations.
2. The maintenance of the following:
   a. Appropriate records to identify the responsible pharmacist or pharmacists in the dispensing and counseling processes.
   b. A mechanism for tracking the prescription or drug order during each step in the processing or dispensing, or both, process.
   c. A mechanism to identify all pharmacies or licensed persons, or both, involved in:
      i. processing;
      ii. filling and dispensing; or
      iii. providing cognitive services.
3. The provision of adequate security to:
   a. protect the product integrity; and
   b. prevent the illegal use or disclosure of protected health information.
4. The maintenance of a continuous quality improvement program for central fill or processing, or both, services.

Rule 38. Credit for Returned Expired Drugs

856 IAC 1-38-1 Applicability

Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 1. (a) This rule establishes the standards and procedures concerning the return of expired legend drugs by an individual or entity licensed to receive legend drugs to either of the following:

1. A drug manufacturer.
2. A designated agent of a drug manufacturer.
(b) This rule does not apply to the following:
1. Vaccines that prevent influenza.
3. Other legend drugs as determined by the board.

856 IAC 1-38-2 "Board" defined

Authority: IC 25-26-13-4
Affected: IC 25-26-13-2

Sec. 2. As used in this rule, "board" has the meaning set forth in IC 25-26-13-2.
856 IAC 1-38-3 "Designated agent" defined

Authority:  IC 25-26-13-4
Affected:  IC 25-26-13

Sec. 3. As used in this rule, "designated agent" means an individual or entity that contracts with a drug manufacturer to administer the manufacturer's drug return policy for expired legend drugs. (Indiana Board of Pharmacy; 856 IAC 1-38-3; filed Jun 27, 2006, 10:50 a.m.: 20060726-IR-856050138FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-38-4 Application of return of expired drugs

Authority:  IC 25-26-13-4
Affected:  IC 25-26-13

Sec. 4. Effective with all drug orders placed after December 31, 2005, all drug manufacturers or their designated agents shall make adequate provisions for the return of expired legend drugs. (Indiana Board of Pharmacy; 856 IAC 1-38-4; filed Jun 27, 2006, 10:50 a.m.: 20060726-IR-856050138FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-38-5 Record keeping

Authority:  IC 25-26-13-4
Affected:  IC 25-26-13

Sec. 5. Drug manufacturers or their designated agents shall do the following:
(1) Maintain records of all credits made under this rule for a period of two (2) years.
(2) Make the records available to the board or its agent upon request.

(Indiana Board of Pharmacy; 856 IAC 1-38-5; filed Jun 27, 2006, 10:50 a.m.: 20060726-IR-856050138FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-38-6 Compliance with other relevant law

Authority:  IC 25-26-13-4
Affected:  IC 25-26-13

Sec. 6. The return of expired legend drugs under this rule shall also be consistent with all other applicable federal, state, and local laws and regulations. (Indiana Board of Pharmacy; 856 IAC 1-38-6; filed Jun 27, 2006, 10:50 a.m.: 20060726-IR-856050138FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

Rule 39. Home Medical Equipment Service Providers

856 IAC 1-39-1 "Board" defined

Authority:  IC 25-26-21-7
Affected:  IC 25-26-21-1

Sec. 1. As used in this rule, "board" has the meaning set forth in IC 25-26-21-1. (Indiana Board of Pharmacy; 856 IAC 1-39-1; filed Jun 27, 2006, 2:00 p.m.: 20060726-IR-856050139FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)
856 IAC 1-39-2 "DMEPOS" defined  
Authority: IC 25-26-21-7  
Affected: IC 25-26-21  

Sec. 2. As used in this rule, "DMEPOS" means durable medical equipment, prosthetics, orthotics, and supplies. (Indiana Board of Pharmacy; 856 IAC 1-39-2; filed Jun 27, 2006, 2:00 p.m.: 20060726-IR-856050139FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-39-3 "Home medical equipment" defined  
Authority: IC 25-26-21-7  
Affected: IC 25-26-21-2  

Sec. 3. As used in this rule, "home medical equipment" has the meaning set forth in IC 25-26-21-2. The term also includes the following:  
(1) Continuous passive motion (CPM) machines.  
(2) Patient lift devices.  
(3) Defibrillators.  
(4) Manual wheelchairs.  
(5) Hospital bed accessories.  
(6) Electronically controlled or computerized wheelchairs and seating systems that are sold. (Indiana Board of Pharmacy; 856 IAC 1-39-3; filed Jun 27, 2006, 2:00 p.m.: 20060726-IR-856050139FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-39-4 "Home medical equipment services" defined  
Authority: IC 25-26-21-7  
Affected: IC 25-26-21-3  

Sec. 4. As used in this rule, "home medical equipment services" has the meaning set forth in IC 25-26-21-3. (Indiana Board of Pharmacy; 856 IAC 1-39-4; filed Jun 27, 2006, 2:00 p.m.: 20060726-IR-856050139FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-39-5 "Licensee" defined  
Authority: IC 25-26-21-7  
Affected: IC 25-26-21  

Sec. 5. As used in this rule, "licensee" means the holder of a home medical equipment service provider license issued under IC 25-26-21 and this title. (Indiana Board of Pharmacy; 856 IAC 1-39-5; filed Jun 27, 2006, 2:00 p.m.: 20060726-IR-856050139FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-39-6 "Provider" defined  
Authority: IC 25-26-21-7  
Affected: IC 25-26-21-4  

Sec. 6. As used in this rule, "provider" has the meaning set forth in IC 25-26-21-4. (Indiana Board of Pharmacy; 856 IAC 1-39-6; filed Jun 27, 2006, 2:00 p.m.: 20060726-IR-856050139FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)
856 IAC 1-39-7 Fees
Authority: IC 25-1-8-2; IC 25-26-21-7
Affected: IC 25-26-21

Sec. 7. (a) The fee for an original licensure application shall be:
(1) one hundred fifty dollars ($150); and
(2) paid at the time of filing the initial application.
(b) The fee for a biennial renewal shall be:
(1) two hundred dollars ($200); and
(2) paid at the time of license renewal.

Indiana Board of Pharmacy; 856 IAC 1-39-7; filed Jun 27, 2006, 2:00 p.m.: 20060726-IR-856050139FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-39-8 Renewal
Authority: IC 25-1-8-2; IC 25-26-21-7
Affected: IC 25-26-21

Sec. 8. Home medical equipment service provider licenses shall expire on December 31 of each odd-numbered year. (Indiana Board of Pharmacy; 856 IAC 1-39-8; filed Jun 27, 2006, 2:00 p.m.: 20060726-IR-856050139FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-39-9 Proof of insurance
Authority: IC 25-1-8-2; IC 25-26-21-7
Affected: IC 25-26-21

Sec. 9. Before being issued a license, each home medical equipment service provider shall obtain and maintain comprehensive business and liability insurance, consistent with minimum Medicare DMEPOS Supplier Standards. (Indiana Board of Pharmacy; 856 IAC 1-39-9; filed Jun 27, 2006, 2:00 p.m.: 20060726-IR-856050139FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-39-10 Oxygen and related respiratory services
Authority: IC 25-26-21-7
Affected: IC 25-26-21; IC 25-34.5

Sec. 10. In order to provide oxygen and related respiratory services, each licensee shall employ or contract with:
(1) a respiratory care practitioner licensed under IC 25-34.5; or
(2) another duly licensed health professional with education and training in oxygen and related respiratory services.
(Indiana Board of Pharmacy; 856 IAC 1-39-10; filed Jun 27, 2006, 2:00 p.m.: 20060726-IR-856050139FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-39-11 Training
Authority: IC 25-26-21-7
Affected: IC 25-26-21

Sec. 11. (a) Each licensee shall conduct and document training for each employee:
(1) at the time of hire; and
(2) annually.
(b) Documentation of training shall be readily available for inspection.
(c) Training programs:
(1) shall be conducted according to industry standards; and
Sec. 12. Each licensee shall maintain patient records, relevant to services rendered, in accordance with state and federal guidelines. (Indiana Board of Pharmacy; 856 IAC 1-39-12; filed Jun 27, 2006, 2:00 p.m.: 20060726-IR-856050139FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-39-13 Equipment maintenance
Authority: IC 25-26-21
Affected: IC 25-26-21

Sec. 13. Each licensee shall maintain documentation of the maintenance of equipment according to industry standards. (Indiana Board of Pharmacy; 856 IAC 1-39-13; filed Jun 27, 2006, 2:00 p.m.: 20060726-IR-856050139FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-39-14 Personnel policies and procedures
Authority: IC 25-26-21
Affected: IC 25-26-21

Sec. 14. Each licensee shall maintain employee personnel records and policies consistent with the following:
(1) The scope of services provided.
(2) State and federal requirements.

856 IAC 1-39-15 Safety and quality of home medical equipment services
Authority: IC 25-26-21
Affected: IC 25-26-21

Sec. 15. Each licensee shall:
(1) clean;
(2) repair;
(3) store;
(4) segregate; and
(5) identify;
all equipment in a manner that makes the equipment safe for use by the public, according to industry standards. (Indiana Board of Pharmacy; 856 IAC 1-39-15; filed Jun 27, 2006, 2:00 p.m.: 20060726-IR-856050139FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-39-16 Licenses
Authority: IC 25-26-21
Affected: IC 25-26-21

Sec. 16. Each licensee shall ensure that each employee is appropriately licensed or credentialed, or both, for the services
856 IAC 1-39-17 Physical location
Authority: IC 25-26-21-7
Affected: IC 25-26-21

Sec. 17. Each licensee shall have a physical location from which home medical equipment services are provided. (Indiana Board of Pharmacy; 856 IAC 1-39-17; filed Jun 27, 2006, 2:00 p.m.: 20060726-IR-856050139FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-39-18 Availability of licensee
Authority: IC 25-26-21-7
Affected: IC 25-26-21

Sec. 18. Each licensee shall provide twenty-four (24) hours a day, seven (7) days a week availability to their clients consistent with the nature of the services the licensee provides. (Indiana Board of Pharmacy; 856 IAC 1-39-18; filed Jun 27, 2006, 2:00 p.m.: 20060726-IR-856050139FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-39-19 Medicare DMEPOS supplier standards
Authority: IC 25-26-21-7
Affected: IC 25-26-21

Sec. 19. The board hereby incorporates by reference the Medicare supplier standards titled Special Payment Rules for Items Furnished by DMEPOS Suppliers and Issuance of DMEPOS Supplier Billing Privileges found at 42 CFR 424.57(c), effective December 11, 2000. (Indiana Board of Pharmacy; 856 IAC 1-39-19; filed Jun 27, 2006, 2:00 p.m.: 20060726-IR-856050139FRA; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

Rule 40. Electronic Prescribing

856 IAC 1-40-1 "Board" defined
Authority: IC 25-26-13-4
Affected: IC 25-26-13-2

Sec. 1. "Board" has the meaning set forth in IC 25-26-13-2. (Indiana Board of Pharmacy; 856 IAC 1-40-1; filed Jan 23, 2006, 8:35 a.m.: 29 IR 1930; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-40-2 "Electronically transmitted" or "electronic transmission" defined
Authority: IC 25-26-13-4
Affected: IC 16-18-2-106.4; IC 25-26-13-2

Sec. 2. "Electronically transmitted" or "electronic transmission" has the meaning set forth in IC 16-18-2-106.4 and IC 25-26-13-2. (Indiana Board of Pharmacy; 856 IAC 1-40-2; filed Jan 23, 2006, 8:35 a.m.: 29 IR 1930; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)
856 IAC 1-40-3 "Electronic data intermediary" or "EDI" defined
   Authority: IC 25-26-13-4
   Affected: IC 25-26-13-2

Sec. 3. "Electronic data intermediary" or "EDI" has the meaning set forth in IC 25-26-13-2. (Indiana Board of Pharmacy; 856 IAC 1-40-3; filed Jan 23, 2006, 8:35 a.m.: 29 IR 1930; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-40-4 "Practitioner" defined
   Authority: IC 25-26-13-4
   Affected: IC 25-26-13-2

Sec. 4. "Practitioner" has the meaning set forth in IC 25-26-13-2. (Indiana Board of Pharmacy; 856 IAC 1-40-4; filed Jan 23, 2006, 8:35 a.m.: 29 IR 1930; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-40-5 "Prescription" defined
   Authority: IC 25-26-13-4
   Affected: IC 25-26-13-2

Sec. 5. "Prescription" has the meaning set forth in IC 25-26-13-2. (Indiana Board of Pharmacy; 856 IAC 1-40-5; filed Jan 23, 2006, 8:35 a.m.: 29 IR 1930; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-40-6 Equipment
   Authority: IC 25-26-13-4
   Affected: IC 25-26-13

Sec. 6. All electronic equipment for receipt of prescription drug orders communicated by way of electronic transmission shall be maintained so as to ensure against the following:
   (1) Unauthorized access.
   (2) Changes to the prescription.
   (Indiana Pharmacy Board; 856 IAC 1-40-6; filed Jan 23, 2006, 8:35 a.m.: 29 IR 1930; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-40-7 Electronic transmission
   Authority: IC 25-26-13-4
   Affected: IC 25-26-13

Sec. 7. Each electronic data intermediary shall ensure that the prescription electronically transmitted to the pharmacy:
   (1) contains:
      (A) no alterations to the:
         (i) prescription;
         (ii) order entry;
         (iii) drug selection; or
         (iv) intended drug selection;
      by any electronic data intermediary;
      (B) the exact information the prescription contained when originated by the authorized practitioner; and
      (C) unique identifier for the practitioner, such as:
         (i) a National Practitioner Identifier (NPI);
(ii) a Drug Enforcement Administration registration number;
(iii) a state issued practitioner license number; or
(iv) another board-approved identifier; and

(2) shall not interfere with the patient's freedom to choose a pharmacy.

(Indiana Board of Pharmacy; 856 IAC 1-40-7; filed Jan 23, 2006, 8:35 a.m.: 29 IR 1930; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-40-8 Electronic data intermediary requirements

Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 8. An applicant for approval as an electronic data intermediary shall do the following:
(1) File an application provided by the board.
(2) Submit information regarding how the EDI shall do the following:
   (A) Guarantee the security of the following:
      (i) The prescription.
      (ii) The practitioner's identity and privacy.
      (iii) The patient's identity, privacy, and confidentiality.
   (B) Validate the authorized practitioner's licensure status.
(3) Appear before the board, if requested.

(Indiana Board of Pharmacy; 856 IAC 1-40-8; filed Jan 23, 2006, 8:35 a.m.: 29 IR 1931; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-40-9 Electronic data intermediary standards

Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 9. Each electronic data intermediary shall do the following:
(1) Maintain policies and procedures regarding the security of the following:
   (A) The prescription.
   (B) The practitioner's identity and privacy.
   (C) The patient's identity, privacy, and confidentiality.
(2) Validate positive identification of the practitioner.

(Indiana Board of Pharmacy; 856 IAC 1-40-9; filed Jan 23, 2006, 8:35 a.m.: 29 IR 1931; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

856 IAC 1-40-10 Electronic prescription prohibitions

Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 10. An electronic prescription does not include a prescription that is as follows:
(1) Transmitted via:
   (A) electronic mail, without the use of an electronic data intermediary; or
   (B) facsimile.
(2) Printed from a computer or electronic device.

(Indiana Board of Pharmacy; 856 IAC 1-40-10; filed Jan 23, 2006, 8:35 a.m.: 29 IR 1931; readopted filed Nov 9, 2012, 11:23 a.m.: 20121205-IR-856120389RFA; readopted filed Nov 21, 2018, 8:35 a.m.: 20181219-IR-856180407RFA)

Rule 41. Cognitive Services
856 IAC 1-41-1 "Cognitive services" defined

Authority:  IC 25-26-13-4
Affected:  IC 25-26-13

Sec. 1. (a) As used in this rule, "cognitive services" means those services provided by a licensed pharmacist (or registered pharmacist intern under the supervision of a licensed pharmacist) that involve the delivery of patient care, counseling, or professional advice that may facilitate pharmaceutical care. The term includes, but is not limited to, the following functions:

1. Medication therapy management.
2. Prospective drug review.
3. Drug utilization review.
4. Drug interaction review.
5. Collaborative practice with eligible prescribers.
6. Pharmacist prescribing where permissible under collaborative practice.
7. Patient counseling (whether in person or via technology that allows the pharmacist to have real-time access to patient data and real-time visual or vocal contact with the patient).
8. Patient education and outreach designed to improve patient outcomes.
10. Facilitating preventative health or disease state management programs.
11. Reducing medication errors.
12. Review and analysis of records of continuous quality improvement programs or protocols.

(b) The term does not include the following activities:

1. Administrative or clerical functions.
2. Third party claims.
3. Sales calls.
4. Record keeping not required to be performed by a pharmacist.
5. Reporting not required to be performed by a pharmacist.
6. Provision of customer service not related to patient counseling on a prescription or drug order review.
7. Duties related to preparation and dispensing of a prescription or drug order that will result in ultimate review by a licensed pharmacist.

(Indiana Board of Pharmacy; 856 IAC 1-41-1; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-41-2 Delivery of cognitive services

Authority:  IC 25-26-13-4
Affected:  IC 25-26-13

Sec. 2. The delivery of cognitive services occurs between a licensed pharmacist (or a registered pharmacist intern under the supervision of a licensed pharmacist) and:

1. a patient;
2. a group of patients;
3. another pharmacist or pharmacists;
4. a prescriber or prescribers; or
5. other eligible health care provider regarding the provision of pharmaceutical care as defined in this article.

(Indiana Board of Pharmacy; 856 IAC 1-41-2; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-41-3 Licensure requirement

Authority:  IC 25-26-13-4
Affected:  IC 25-26-13
INDIANA BOARD OF PHARMACY

Sec. 3. In order to provide or deliver cognitive services, an individual must have an active license in good standing in a state that has at least the same minimum standards for licensure as the state of Indiana including, but not limited to, passage of the North American Pharmacist Licensure Examination (NAPLEX). (Indiana Board of Pharmacy; 856 IAC 1-41-3; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

Rule 42. Remote Pharmacy Practice

856 IAC 1-42-1 "Remote pharmacy practice" defined
Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 1. "Remote pharmacy practice" means the provision of pharmaceutical services not related to physically handling or dispensing pharmaceutical drugs or devices. This rule is intended to govern the practice of licensed pharmacists acting as independent contractors whether or not directly employed or affiliated with an entity that is licensed by the board to practice pharmacy into or out of the state of Indiana. This service also does not include the provision of pharmaceutical care that is conducted within the physical confines or premises of a permitted in-state pharmacy or a registered nonresident pharmacy. This rule is not intended to overrule or supersede the provisions, practices, and requirements listed in 856 IAC 1-37. (Indiana Board of Pharmacy; 856 IAC 1-42-1; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-42-2 Permissible activities
Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 2. The following are permissible activities covered by the remote practice pharmacy:
(1) Perform processing functions.
(2) Consulting services by contract with a dispensing pharmacy.
(3) Claims adjudication.
(4) Remote order/entry.
(5) Remote order review and approval.
(6) Other cognitive services as defined in 856 IAC 1-41.
(Indiana Board of Pharmacy; 856 IAC 1-42-2; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-42-3 Requirements for licensure
Authority: IC 25-26-13-4
Affected: IC 25-26-13

Sec. 3. Individuals who wish to engage in the remote practice of pharmacy in or into the state of Indiana as provided in this rule must satisfy the following licensure requirements:
(1) Have an active Indiana pharmacist license.
(2) Provide evidence, upon board request, of continuing education and any other relevant training for services provided.
(3) Have a license in good standing with no current or pending discipline (that is, ongoing probation) in this state or any other state in which the individual is licensed, unless otherwise approved by the board following a personal appearance.
(Indiana Board of Pharmacy; 856 IAC 1-42-3; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-42-4 System, access, security, and privacy requirements
Authority: IC 25-26-13-4
Affected: IC 25-26-13
Sec. 4. Pharmacists that provide or engage in remote practice of pharmacy services must employ security and privacy standards and protocols that adequately protect patient privacy and health. Accordingly, a pharmacist must satisfy the following requirements:

1. Utilize a system that is capable of the following:
   - Real-time access and exchange of live patient data.
   - Secure and encrypted mediums of exchange.
   - Limited access portals with rigorous authentication and identification protocols.
   - Providing back-up or disaster recovery capability in the event of failure or loss of service.

2. Utilize a system or program that at a minimum is capable of maintaining the following information on each transaction, service, prescription, or drug order reviewed, entered, or provided by the pharmacist performing the service:
   - An electronic record that can be reproduced in electronic or manual format for inspection or review at any point within the scope of the appropriate record retention requirement as stipulated by either state or federal law.
   - Track the identity of the individual pharmacist that took an action and the date and time at which this action took place.

3. Utilize a system capable of maintaining compliance with HIPAA and other state or federal, or both, laws and regulations that relate to patient privacy.

4. Utilize a system approved and reviewed by the board or board staff following a personal appearance or petition to the board.

(Indiana Board of Pharmacy; 856 IAC 1-42-4; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-42-5 Record keeping requirements and notice

Authority:  IC 25-26-13-4
Affected:  IC 25-26-13

Sec. 5. Pharmacists that engage in remote practice of pharmacy services are required to:

1. maintain appropriate records; and

2. make the records available for inspection and review upon board request.

Retention requirements shall be documented in a pharmacist's policies and procedures and also made available for review by the board. Length of retention stipulated in the policy should reflect any applicable state or federal, or both, requirements. (Indiana Board of Pharmacy; 856 IAC 1-42-5; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-42-6 Work environment for remote practice of pharmacy

Authority:  IC 25-26-13-4
Affected:  IC 25-26-13

Sec. 6. Remote pharmacy practice shall be conducted in a work environment that is conducive to providing quality patient treatment decisions, private counseling, or other health care related activities permissible under 856 IAC 1-41 but that do not include dispensing. Individuals that practice remotely are prohibited from practicing in a space that serves as their primary living, household, or family space. For example, if working out of a home environment, the individual should perform this work in a dedicated office space that is not actively used as a bedroom, living room, or other miscellaneous family space. This space should be open and accessible for an inspection by board staff if required. Work product or equipment in this space should be capable of being properly secured to protect patient privacy. (Indiana Board of Pharmacy; 856 IAC 1-42-6; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)

856 IAC 1-42-7 Policies and procedures

Authority:  IC 25-26-13-4
Affected:  IC 25-26-13

Sec. 7. A pharmacist that is providing remote practice of pharmacy services shall develop, implement, review, revise, and
comply with policies and procedures for the services they provide. These policies and procedures should reflect the nature and extent of the services they perform. In the event a pharmacist is performing services via a contract with another service provider, dispensing pharmacy, or other institution, their contract shall stipulate or designate, or both, whose policies and procedures control for the services being performed. At a minimum, the policies and procedures shall include the following:

1. A policy or statement concerning the services being provided or performed.
2. A policy outlining the responsibilities of each of the parties involved.
3. A policy or list that documents the names, addresses, telephone numbers, and all license and permit numbers of the parties involved in the services to be performed.
4. A policy that documents the protection, confidentiality, and integrity of patient information.
5. A policy that addresses record maintenance.
6. A policy that addresses any necessary additional mechanisms or controls for compliance with other federal and state laws.
7. A policy for operating and maintaining a continuous quality improvement program for remote practice of pharmacy services, designed to objectively and systematically monitor and evaluate the quality and appropriateness of patient care, pursue opportunities to improve patient care, and resolve identified problems.

(Indiana Board of Pharmacy; 856 IAC 1-42-7; filed Jun 19, 2013, 10:06 a.m.: 20130717-IR-856120619FRA; readopted filed Nov 18, 2019, 11:41 a.m.: 20191218-IR-856190076RFA)